study_arm,TrialID,url,Interventions,vaccine,conventional,traditional
im,ACTRN12617001086358,http://www.anzctr.org.au/ACTRN12617001086358.aspx,"This is a pilot case control study to study the effect, if any, of obesity, on the immune response to the annual licensed quadrivalent influenza vaccination in Australian children aged 11-17 years.<br>Cases -  25 obese children (BMI >=95th percentile for age and gender) aged 11-17 years.<br>Controls - 25 non-obese children (BMI 5th - <95th percentile for age and gender) aged 11-17 years.<br>The dose of the influenza vaccine is 0.5 ml administered as a single dose IM injection. All vaccines will be administered by a qualified and experienced practitioners (medical officer or registered nurse) within the unit, according to current vaccination guidelines. <br>All participants will have bloods samples collected by the recruiting medical officer before vaccination and at the follow-up visits at 1 and 6 months after vaccination.",Yes,NA,NA
im,ACTRN12618001090202,https://anzctr.org.au/ACTRN12618001090202.aspx,"The study treatment will consist of an infusion of CD34 selected donor stem cells on day 0 of the fully-matched related allogeneic bone marrow transplant. A minimum of 21 days following the transplant, one intravenous infusion of 2 x 107/m2 of pathogen specific T cells will be given over 1 minute to all patients following myeloid engraftment. In addition, up to a total of four intravenous infusions of 2x107/m2 either WT1 specific T cells for patients with AML or CAR19 T cells for patients with ALL will be given to the patient no less than 28 days apart unless contraindicated. Such contraindications are fever, hypotension, tachycardia, hypoxemia, graft versus host disease greater than or equal to grade II in the week prior to infusion, abnormal liver function >3x upper limit normal. The pathogen specific and malignancy specific cells can be given and monitored as an outpatient (eg: the Cancer Day Suite) by study investigators or other staff as delegated by the investigator's (eg: BMT Fellow, Clinical Nurse Specialists, Nurse Practitioners). The patients will be followed up at 3 months post transplant and 6 months post transplant.  ALL patients will be followed up at additional time points of 12months and yearly for 15 years for the detection of long term adverse event outcomes.  The bone marrow transplant will occur and delivered as an inpatient as per standard of care.",NA,Yes,NA
main,ACTRN12619000423112,https://anzctr.org.au/ACTRN12619000423112.aspx,"(1) Initial therapy with Mirabegron (50 mg/day) for 12 weeks.<br>-Mirabegron (produced by Astellas Pharmaceuticals) is a film-coated prolonged release oral tablet and it will be administered at a dose of 50 mg/day. <br>OR<br>(2) Placebo <br><br>Strategies used to monitor adherence to the intervention:<br>-At 4 weeks and 12 weeks participants will be self-reporting medication adherence (patient diary). <br>-Participants will be instructed to return unused capsules at 12 weeks and returned capsules will be counted by the study team and returned to Pharmacy department at RNSH<br>-Blood tests through the whole study (Screening, baseline, Week 4, Week 12).<br><br>",NA,NA,NA
main,ACTRN12619000720112,https://anzctr.org.au/ACTRN12619000720112.aspx,68Ga-PSMA-PET/CT scan will be administered in a registered nuclear medicine department by a nuclear med physician. This scan is considered standard of care for patients and this trial requires 1 additional scan under the same conditions as a standard PSMA scan. All participants are will be undergoing enzalutamide as standard of care. PSMA scans takes approx. 2-3 hours to complete.  The second scan will be 7 weeks from the baseline scan. The Enzalitamide dosing is based on clinician choice (medical oncologist) Enzalutimdie will commence at Week 5 (4 weeks post the 1st PSMA Scan) will continue throughout study as prescribed by treating Med Onc.,NA,NA,NA
im,ACTRN12619000828123,https://anzctr.org.au/ACTRN12619000828123.aspx,"Intervention: Early Inotropes: <br>Early Inotropes: Goal-Directed Therapy with initiation of intravenous inotropes after the initial fluid bolus (20ml/kg, minimal amount 10-20ml/kg fluid bolus;  (or 500-1000ml fluid bolus in patients >50kg). The inotrope used is diluted adrenaline initiated at 0.05 to 0.1 (up to 0.3) mcg/kg/min. Dilution is used to fasten drug delivery and response to drug rate changes, to reduce risks with extravasation, and to facilitate peripheral application. Adrenaline will be prepared in 50ml syringes in 5% Dextrose solution that will be connected to peripheral, intraosseus, or central vascular access device. Drug delivery will occur through guardrails or similar system to ensure safe delivery of applied standardized drug concentrations. <br><br>The study treatment will be given as continuous infusion for the duration of resuscitation until resolution of shock, discharge from intensive care unit, death, decision of the treating physician to stop or replace with other inotrope, or occurrence of major side effects, whichever occurs first. <br>Compliance with protocol will be assessed through the prospective institutional drug charts, and the prospective study case report form<br>",NA,NA,NA
covid,ACTRN12620000731998,https://anzctr.org.au/ACTRN12620000731998.aspx,"This is a multisite, 3 stage inpatient study of the Angiotensin II Receptor Blocker Losartan for treatment of COVID-19. The three stages will be recruited sequentially. <br><br>In the first stage, 9 participants will be allocated to the active treatment. The first intervention studied will be Losartan 25mg tablet once daily, for 7 days, or their entire admission (whichever is longer).<br><br>Following complete recruitment to the first stage, participants will be allocated to the second stage of the study. In the second stage, 9 participants will start at 25mg Losartan. If hemodynamically stable after 24 hours, they will increase dose to 25mg twice daily for 7 days, or their entire admission (whichever is longer).<br>If not (clinical decision) the participant will stay on 25mg daily for 7 days, or the remainder of for their admission (whichever is longer).<br><br>Following complete recruitment to the first and second stages, participants will be allocated to the third stage of the study. In the third stage, 9 participants will start on 25 mg Losartan daily. If hemodynamically stable after 24 hours, they will increase dose to 25mg twice daily. Then, if hemodynamically stable after further 24 hours, they will increase dose again to 25mg morning and 50mg night. After a further 24 hours, and if the participant is hemodynamically stable, they will increase dose to 50mg twice daily for 7 days, or the remainder of for their admission (whichever is longer).<br><br>For all stages, the dose will be held if the blood pressure systolic reading is less than 100mmHg, and/or a renal function decrease of greater than 30% from baseline is observed, or serum potassium greater than permitted by the institutional upper limit of normal (ULN) occurs. <br><br>Losartan will be restarted at the",NA,NA,NA
im,ChiCTR-IIR-16008507,http://www.chictr.org.cn/showproj.aspx?proj=14377,trial group:2 dose  of trial vaccine (trivalent) for 21 days interval (+/- 7days);control group A:2 dose of vaccine A (tetravalent) for 21 days interval (+/- 7days);Control group B:2 dose of vaccine B (trivalent) for 21 days interval (+/- 7days);,Yes,NA,NA
im,ChiCTR-IPQ-16008781,http://www.chictr.org.cn/showproj.aspx?proj=14665,Group A:Dexamethasone;Group B:Placebo ;,NA,Yes,NA
im,ChiCTR1800014694,http://www.chictr.org.cn/showproj.aspx?proj=25120,"control group:conventional treatment based on the use of antimicrobial therapy;Combination group:On the basis of the treatment of the control group, the combination of ulinastatin;",NA,NA,NA
main,ChiCTR1900022258,http://www.chictr.org.cn/showproj.aspx?proj=36344,intervention group:Coenzyme Q10 400mg;placebo:placebo;,NA,NA,NA
main,ChiCTR1900022351,http://www.chictr.org.cn/showproj.aspx?proj=35137,GP IIb/IIIa group:tirofiban;LWMH group:enoxaparin;,NA,NA,NA
main,ChiCTR1900022488,http://www.chictr.org.cn/showproj.aspx?proj=37970,"Puerarin group:Puerarin capsule (50mg/time), 3 times a day + Statins;Control group:Statins;",NA,NA,NA
im,ChiCTR1900023507,http://www.chictr.org.cn/showproj.aspx?proj=31221,Experimental groups:Different anesthetic drugs; Intravenous ketamine was administered as soon as dexmedetomidine induction;,NA,NA,NA
main,ChiCTR1900023825,http://www.chictr.org.cn/showproj.aspx?proj=39847,Standard dual antibody group(A):Oral standard dose and time of dual antiplatelet drugs;Standard dose ticagrelor monoclonal antiplateletStandard dose tigrilol monoclonal antiplatelet:The duration of dual antiplatelet therapy was shortened to standard dose ticagrelor monoclonal antiplatelet therapy;Low dose ticagrelor monoclonal antiplatelet(C):The duration of dual antiplatelet therapy was shortened to low dose ticagrelor monoclonal antiplatelet therapy;,NA,NA,NA
im,ChiCTR1900024894,http://www.chictr.org.cn/showproj.aspx?proj=41373,S group:Moderate sedation with low dose propofol combined with sufentanil;Control group:Slow intravenous injection of propofol 1.5-2.5 mg/kg until the patient holds a 20 ml syringe and drops off;,NA,NA,NA
main,ChiCTR1900025842,http://www.chictr.org.cn/showproj.aspx?proj=43207,"Esperimental group:Standardized treatment of acute coronary syndrome + Tongxinluo capsule 4 capsules / time, 3 times / day, oral;Control group:Standardized treatment of acute coronary syndrome + Tongxinluo capsule placebo 4 capsules / time, 3 times / day, oral;",NA,NA,NA
main,ChiCTR1900026242,http://www.chictr.org.cn/showproj.aspx?proj=43382,Experimental group:subcutaneous injection of low molecular weight heparin;Control group:Symptomatic supportive treatment of traditional hepatoprotective and diuretic therapy;,NA,Yes,NA
main,ChiCTR1900026494,http://www.chictr.org.cn/showproj.aspx?proj=44030,Experimental group:Vitmin D3;Control group:D-Cal calcium;,NA,NA,NA
main,ChiCTR1900027146,http://www.chictr.org.cn/showproj.aspx?proj=45130,Ara-c+6-TG:Ara-c+6-TG;ATRA+RIF:ATRA+RIF;,NA,NA,NA
main,ChiCTR1900027678,http://www.chictr.org.cn/showproj.aspx?proj=44407,single arm:CD19/BCMA CAR-T therapy;,NA,NA,NA
im,ChiCTR1900028497,http://www.chictr.org.cn/showproj.aspx?proj=42626,Experimental group:Oseltamivir phosphate capsules +  Chai-shi-Tui-Re granules;Control Group:Oseltamivir phosphate capsules + Placebo of Chai-shi-Tui-Re granules;,NA,Yes,NA
covid,ChiCTR2000029813,http://www.chictr.org.cn/showproj.aspx?proj=49425,"Experimental group:Conventional Treatment & Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;",NA,NA,NA
covid,ChiCTR2000030033,http://www.chictr.org.cn/showproj.aspx?proj=49703,"Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral ""Wu-Zhi-Fang-Guan-Fang"" decoction;Control group:Routine quarantine measures;",NA,NA,NA
covid,ChiCTR2000030089,http://www.chictr.org.cn/showproj.aspx?proj=49889,Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;,NA,Yes,NA
covid,ChiCTR2000030170,http://www.chictr.org.cn/showproj.aspx?proj=50017,"severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;",NA,NA,NA
covid,ChiCTR2000030469,http://www.chictr.org.cn/showproj.aspx?proj=50082,Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;,NA,NA,NA
covid,ChiCTR2000030804,http://www.chictr.org.cn/showproj.aspx?proj=51018,Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;,NA,NA,NA
covid,ChiCTR2000030944,http://www.chictr.org.cn/showproj.aspx?proj=50199,"Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;",NA,NA,NA
covid,ChiCTR2000031453,http://www.chictr.org.cn/showproj.aspx?proj=51859,Nintedanib group:Nintedanib;Control group:Placebo;,NA,NA,NA
covid,ChiCTR2000039000,http://www.chictr.org.cn/showproj.aspx?proj=62581,placebo group:placebo;vaccine group:vaccine;,Yes,NA,NA
im,CTRI/2017/09/009849,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18803,"Intervention1: Group I: Enteral ivabradine 2.5 mg every 6 hours, titrated to heart rate.<br>Intervention2: Group I: Enteral ivabradine 2.5 mg every 6 hours, titrated to heart rate, in addition to standard treatment of septic shock.<br>Control Intervention1: Group S: standard therapy for septic shock<br>Control Intervention2: Group S: Standard treatment for septic shock<br>",NA,NA,NA
im,CTRI/2017/11/010688,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11981,Intervention1: Inj. Sildenafil: 0.5mg/kg/dose over 3 hrs three times daily for 3 days or drop in Right ventricular systolic pressure to half the systemic pressure whichever is earlier<br>Control Intervention1: Normal Saline (0.9%): same dose as the intervention drug (sildenafil) for 3 days or drop in Right ventricular systolic pressure to half the systemic pressure whichever is earlier<br>,NA,NA,NA
main,CTRI/2019/01/017332,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30522,"Intervention1: Zolpidem Tartrate: Zolpidem is indicated for the short-term treatment of insomnia. The treatment should be taken in a single intake and not be re-administered during the same night. The recommended daily dose for adults is 10 mg to be taken orally immediately at bedtime. The lowest effective daily dose of Zolpidem tartrate should be used and must not exceed 10 mg. The duration of treatment should usually vary from a few days to two weeks with a maximum of four weeks including tapering off where clinically appropriate. As with all hypnotics, long-term use is not recommended.<br>Dose : Daily 1 tablet orally in Night <br>Duration : 3 Weeks treatment/patient<br>Control Intervention1: Not Applicable: Not Applicable<br>",NA,NA,NA
main,CTRI/2019/02/017505,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31033,"Intervention1: Natural Killer cells: Single Infusion of optimized natural killer cells derived from haplo- identical family donors.<br>With unstimulated apheresis, we would expect about 109 to 1010 mononuclear cells being separated. Of these, about 10% would constitute NK cells. Thus after CD3 depletion and CD56 positive selection, we would have about 108 to 109 NK cells. The isolated NK cells (to a final concentration of not less than 2Ã?106/mL) will be suspended overnight in plasmalyte (50 to 100 mL) supplemented with 20% autologous plasma, 500 U/mL interleukin (IL)-2 (Aldesleuchina, ProleukinÂ®) and 1 Î¼M arsenic trioxide (ATO) at 37 Â°C<br>Control Intervention1: Not applicable: Not applicable<br>",NA,Yes,NA
main,CTRI/2019/02/017575,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31281,Intervention1: caudal analgesia: inj bupivacaine local anesthetic agent along with inj morphine 50 mcg/kg given in caudal epidural space as analgesia<br>Intervention2: thoracic epidural analgesia: with 20 g needle  24 g catheter insertedin T5-T7 epidural space.inj bupivacaine with inj fentanyl 3 mcg/kg/hr as infusion intra op and post operatively<br>Control Intervention1: intravenous analgesia: inj fentanyl infusion 2 mcg/kg.hr<br>,NA,Yes,NA
main,CTRI/2019/02/017661,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31293,"Intervention1: arka pratisaraneeya kshara: the whole plant of arka (calotropis procera)are burnt, the ash is collected and added water and reduced by heating and sankh nabhi, etc were mixed and final form of drug was obtained.<br>Control Intervention1: apamarga pratisaraneeya kshara: the whole plant of apamarga (achyranthes aspera linn.)are burnt, the ash is collected and added water and reduced by heating and sankh nabhi, etc were mixed and final form of drug was obtained.<br>",NA,NA,NA
main,CTRI/2019/04/018410,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31674,Intervention1: group A: Nasya with bhringraj taila for a period of 45 days.<br>Dose: 6-8 drops Marsha<br>1-2 Drops Pratimarsha<br>In B/W the sitting of marsha pratimarsha will be given<br>Control Intervention1: group B: Nasya with double concentration bhringraj taila<br>,NA,NA,NA
main,CTRI/2019/04/018467,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32630,"Intervention1: Gabapentin and Amitryptiline,in addition to<br>conventional DMARDs: Gabapentin will be administered<br>starting with a dose of 300mg once daily for 5 days followed by 300mg twice daily for 5 days and<br>finally 300mg three times daily to continue for 16 weeks till end of study. <br>Amitryptiline will be given in a dose of<br>10 mg daily at 8.00p.m. for 16 weeks till end of study.<br>Control Intervention1: continue only with Disease Modifying Anti Rheumatic Drugs: Methotraxate, Sulfasalazine, Hydroxychloroquine in recommended dose either singly or in combination<br>",NA,Yes,NA
main,CTRI/2019/04/018681,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30558,"Intervention1: Inj zoledronic acid infusion at 1st week: Injection Zoledronic acid 5mg/100ml i.v. slowly over 1 hour at first week of fracture, dosage is once in a year<br>Control Intervention1: Inj Zoledrinic acid infusion at 6 weeks: Injection Zoledronic acid 5mg/100ml i.v. slowly over 1 hour at 6 weeks of fracture,dosage is once in a year<br>Control Intervention2: No Inj Zoledronic acid infusion: No Inj Zoledronic acid infusion to patients<br>",NA,NA,NA
main,CTRI/2019/05/018959,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32290,Intervention1: Etelcalcetide (AMG 416): Etelcalcetide (AMG 416) IV TIW  (3 times per week)<br>Control Intervention1: Not Applicable: Not Applicable<br>,NA,NA,NA
im,CTRI/2019/05/019109,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33492,Intervention1: 10 sprays of 10% topical lignocaine: 10 sprays of 10% topical lignocaine would be applied on the pharynx prior to flexible bronchoscopy and the outcomes would be assessed<br>Control Intervention1: 5 sprays of 10% topical lignocaine: 5 sprays of 10% topical lignocaine would be applied on the pharynx prior to flexible bronchoscopy and the outcomes would be assessed<br>,NA,Yes,NA
im,CTRI/2019/07/020174,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34335,Intervention1: ORAL AMOXICILLIN<br>: 100 MG/KG/DAY TDS 7 TO 10 DAYS<br><br>Intervention2: INJECTABLE 3rd GENERATION CEPHALOSPORIN: 100 MG/KG/DAY BD FOR 7 TO 10 DAYS<br>Control Intervention1: INJECTABLE 3rd GENERATION CEPHALOSPORIN: 100 MG/KG/DAY BD FOR 7 TO 10 DAYS<br>,NA,NA,NA
main,CTRI/2019/08/020943,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27713,"Intervention1: 1. NEXAGON High Dose Concentration<br>Other Name: CODA001<br><br>2. NEXAGON Low Dose Concentration<br>Other Name: CODA001: Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br><br>Intervention2: 2. NEXAGON Low Dose Concentration<br>Other Name: CODA001<br>: Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br>Control Intervention1: NEXAGON Vehicle (placebo): Applied under a bandage contact lens and to the fornices of the eye on multiple days over a 28-day Treatment Period. If corneal re-epithelialization occurs during the Treatment Period, the treatment will be withheld and the participant will enter a 28-day Follow-up Period to assess durability of the corneal epithelium.<br>NOTE: An additional application of open-label NEXAGON High Dose Concentration is available on the final day (Day 28) of the Treatment Period for those participants still present with a PED.<br><br>",NA,NA,NA
covid,CTRI/2020/06/025650,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44412,Intervention1: Joshanda (Decoction) and Khameera Marwareed: Joshanda (Decoction) of the following<br><br>1. Behidana (Cydonia oblonga) 3 gm<br>2. Unnab (Zizyphus jujube)<br>5 in number <br>3. Sapistan (Cordia myxa)<br>9 in numbers<br><br>Dose: 125 ml OD morning<br>Route of Administration: Orally<br><br>and<br><br>Khameera Marwareed<br><br>Dose: 5g OD morning<br>Route of Administration: Orally<br>Control Intervention1: NIL: Subjects not receiving Unani prophylactic regimen<br>,NA,NA,NA
covid,CTRI/2020/06/025998,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707,Intervention1: Raj Nirwan Bati capsule: 1. Mercury (Para)<br>2. Sulphur (Gandhak)<br>3. Gold (Sona)<br>4. Silver (Chandi)<br>5. Clamina Perpeta<br>6. Arsenic Trioxide (Hartal Bhasma)<br>7. Black pepper (Kaali Mirch)<br>8. Naag Damanti (Snake Plant)<br>9. Celery (Azwaiyan)<br>10. Zinc<br>11. Niramish (Mahamash oil)<br><br>One Raj Nirwan Bati capsule of 125 mg (1 Ratti) twice a day empty stomach for 12 days<br>Control Intervention1: Placebo: Sugar gelatin capsule<br>with 4 small balls of sugar <br>twice a day empty stomach for 12 days<br>,NA,NA,NA
covid,CTRI/2020/07/026471,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45318,Intervention1: Kaba Sura Kudineer: 60ml BD for 14 days<br>Intervention2: Tab. Amukkarachooranam: 2 BD for 14 days<br>Intervention3: Tab. Athimathuram: 2 BD for 14 Days<br>Intervention4: Tab. Brahmanandha Bairavam: 100mg 1BD for 14 days<br>Intervention5: Adathodai Manappagu: 10ml with 30ml water  BD for 14 days<br>Intervention6: Thippili Rasayanam: 5gm BD for 14 days<br>Intervention7: Notchi Kudineer: 60ml BD for 14 Days<br>Control Intervention1: Not Applicable: Not Applicable<br>,NA,NA,NA
covid,CTRI/2020/07/026514,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45580,"Intervention1: Resveratrol-Copper tablets: Patients will be administered orally, tablets of R-Cu containing 5.6 mg of Resveratrol and 560 ng of copper, 1 tablet once every 6 hours, from the date of randomization till the day of discharge, or death, whichever is earlier. They will also receive the Standard Treatment<br>Intervention2: Chlorophyllin tablets: Patients will be administered orally, tablets of chlorophyllin, 1 tablet of 750 mg once every day, on empty stomach in the morning, from the date of randomization till the day of discharge, or death, whichever is earlier. They will also receive the Standard Treatment .<br>Control Intervention1: Standard treatment: Patients in this arm can receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs. However, patients in this arm cannot receive Resveratrol -Copper treatment. The treatment proptocol will be in sync with the emerging scientific evidence and evolving national guidelines<br>",NA,Yes,NA
covid,CTRI/2020/07/026789,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45111,"Intervention1: ArtemiC medical spray: ArtemiC is a Oromucosal  medical spray combined of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (15 mg/ml) and vitamin C (60 mg/ml) in spray administration.<br>given as add-on therapy, 2 times a day, on Days 1 and 2.Each dose contains 1ml (10 puffs-pushes on the spray bottle) , total daily dose 2ml (20 puffs- pushes on the spray bottle).The total treatment is 40 puffs for 2 days.<br>Control Intervention1: Placebo: Placebo is a Oromucosal  medical spray will be given as add-on therapy, 2 times a day, on Days 1 and 2.<br>Each dose contains 1ml (10 puffs-pushes on the spray bottle) , total daily dose 2ml (20 puffs- pushes on the spray bottle).The total treatment is 40 puffs for 2 days.<br>",NA,NA,Yes
covid,CTRI/2020/08/027038,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46197,Intervention1: Triozone: 1 ml of trio zone mixed with 4 ml of normal saline given 3 times a day from nasal route   . a cumulative 5ml  single dose is used for nebulisation by nasal route once a day  .<br>Control Intervention1: Placebo: 5ml of 0.9 % normal saline will be used as placebo given by nasal route . thrice  a day  at same doses of trial drug. Normal saline do not have any effects over virus replication and free of any side effects.<br>,NA,NA,NA
covid,CTRI/2020/08/027503,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44980,Intervention1: Aspirin: Low dose aspirin (75 mg OD) for 10 days along with standard of care<br>Control Intervention1: Standard of Care: Standard of care will included standard practice of the institute at that time<br>,NA,NA,NA
covid,CTRI/2020/09/027904,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47392,Intervention1: Autologous whole blood injection: 2.5 ml of blood will be drawn from a vein in the cubital fossa with a 20G needle and a 5 ml syringe and the drawn blood will be<br>immediately (within 2 minutes) injected intramuscularly into the gluteal muscle of the same subject (once a day) from whom the blood was drawn on day on Day 1 and Day 3.<br>Control Intervention1: Standard therapy for Covid therapy: Treatment protocol for Covid 19 infection will be followed as per ICMR recommendations<br>,NA,NA,NA
covid,CTRI/2020/09/028088,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47829,"Intervention1: Colchicine, Aspirin and Montelukast: Intervention: The intervention arm will receive, in addition to the standard of care, the following drugs:<br>	Colchicine - 0.6 mg per oral, 12 hourly till discharge<br>	Aspirin - 325 mg per oral 6 hourly till discharge<br>	Montelukast - 10 mg per oral once a day till discharge<br><br>Control Intervention1: Standard of Care: Standard of Care in Covid-19<br>",NA,NA,NA
covid,CTRI/2020/10/028277,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47691,"Intervention1: Thymosin Î±-1-1.6 mg Injection <br> along with SOC: Each vial contains : Thymosin Alpha 1-1.6mg<br>Excipients...... q.s (Lyophilized)<br>Sterile water for Injections IP 1ml Ampoule<br>Manufactured by: Gufic Biosciences Ltd., India<br>Dose:Thymosin Î±-1-1.6 mg x 2 injections<br>Frequency: Twice daily(Moderate)and Thrice daily (Severe)<br>Route of administration: Subcutaneous <br>Total Duration 7 days<br><br><br>Control Intervention1: Placebo Injection along with SOC: Each vial contains : Excipients...... q.s (Lyophilized)<br>Sterile water for Injections IP 1Ml Ampoule<br>Manufactured by: Gufic Biosciences Ltd., India<br>Dose: Placebo x 2 injections<br>Frequency: Twice daily(Moderate)and Thrice daily (Severe)<br>Route of administration: Subcutaneous <br>Total Duration 7 days<br><br><br>",NA,NA,NA
covid,CTRI/2020/10/028635,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48783,Intervention1: Virunil 500mg Capsules: 1500mg per day in divided doses (3doses per day) with water.<br>for up to maximum of 10 days. Mode of Administration: Oral<br><br>Control Intervention1: Standard Supportive Care: These patients will be managed by standard supportive care.<br>,NA,NA,NA
im,DRKS00017475,http://www.drks.de/DRKS00017475,Intervention 1: The intervention group receives human albumin intravenously. The dose begins with a starting dose of 60 g of human albumin 20% for 2-3 h and is from study day 1 after randomization depending on the albumin serum value:<br>= 30 g / l: no administration<br>= 25 g / l and <30 g / l: 40 g for 1-2 h<br>= 20 g / l and <25 g / l: 60 g for 2-3 h<br><20 g / l: 80 g over 3-4 h<br>customized.<br>The duration of the application is a maximum of 28 days after randomization. Intervention 2: The control group will receive the standard therapy of septic shock with any crystalloids as volume replacement therapy of first choice.,NA,NA,NA
im,EUCTR2006-005558-63-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005558-63,<br>Trade Name: FLUAD<br>Product Name: FLUAD<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>Trade Name: Agrippal<br>Product Name: Agrippal<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>,NA,NA,NA
im,EUCTR2013-004614-18-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004614-18,<br>Trade Name: Zevtera©<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Ceftobiprole medocaril sodium<br>CAS Number: 252188-71-9<br>Current Sponsor code: BAL5788-001<br>Other descriptive name: CEFTOBIPROLE MEDOCARIL SODIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 666.6-<br><br>,NA,NA,NA
im,EUCTR2014-001097-34-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001097-34,<br>                Product Name: MEDI4893<br>                Product Code: MEDI4893<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: NA<br>                CAS Number: NA<br>                Current Sponsor code: MEDI4893<br>                Other descriptive name: MEDI4893<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2015-003026-14-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003026-14,<br>Product Name: Delafloxacin<br>Product Code: RX-3341-83<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Delafloxacin meglumine<br>CAS Number: 352458-37-8<br>Current Sponsor code: RX-3341-83<br>Other descriptive name: DELAFLOXACIN MEGLUMINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Product Name: Delafloxacin oral tablet<br>Product Code: RX-3341-83<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Delafloxacin meglumine<br>CAS Number: 352458-37-8<br>Current Sponsor code: RX-3341-83<br>Other descriptive name: DELAFLOXACIN MEGLUMINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 450-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Moxifloxacin<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1.6-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Moxifloxacin<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>Product Name: Linezolid<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Linezolid<br>CAS Number: 165800-03-3<br>Other descriptive name: LINEZOLID<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administr,NA,Yes,NA
im,EUCTR2015-003119-39-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003119-39,<br>Trade Name: stilnox<br>Product Name: zolpidem<br>Pharmaceutical Form: Buccal tablet<br>Pharmaceutical form of the placebo: Buccal tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2015-004546-26-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004546-26,<br>Product Code: VIS410<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: VIS410<br>Other descriptive name: VIS410<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2015-005383-42-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005383-42,"<br>Trade Name: Anxut 5 mg<br>Pharmaceutical Form: Capsule, soft<br>INN or Proposed INN: BUSPIRONE<br>Current Sponsor code: BUSPIRONE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>",NA,Yes,NA
im,EUCTR2015-005482-23-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005482-23,"<br>Product Name: Quadrivalent Influenza Vaccine <br>Product Code: QIV<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: QIV<br>Other descriptive name: quadrivalent influenza vaccine <br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Trade Name:  Influvac® <br>Product Name: Influvac (Tiv containing B Yamagata strain) <br>Product Code: TIV (Yam)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: TIV (Yam)<br>Other descriptive name: trivalent influenza vaccine (Yam)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Influvac (TIV containing B-Victoria strain)<br>Product Code: TIV (Vic)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: TIV (Vic)<br>Other descriptive name: trivalent influenza vaccine (Vic)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>",Yes,NA,NA
im,EUCTR2016-001557-41-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001557-41,"<br>Product Name: AdimFlu-S (QIS)<br>Product Code: AdimFlu-S (QIS)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>Current Sponsor code: A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A<br>Other descriptive name: A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Other descriptive name: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/BRISBANE/60/2008 - DERIVED STRAIN USED NYMC BX-35<br>Other descriptive name: B/BRISBANE/60/2008 - DERIVED STRAIN USED NYMC BX-35<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Other descriptive name: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Trade Name: a-RIX-Tetra<br>Product Name: a-RIX-Tetra<br>Product Code: a-RIX-Tetra<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>Current Sponsor code: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Other descriptive name: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Other descriptive name: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008,",NA,NA,NA
im,EUCTR2016-003433-20-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003433-20,<br>                Trade Name: kineret<br>                Product Name: kineret<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: ANAKINRA<br>                CAS Number: 143090-92-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
im,EUCTR2016-004009-15-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004009-15,<br>                Product Code: VIS410<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: VIS410<br>                Current Sponsor code: VIS410<br>                Other descriptive name: VIS410<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2016-004133-25-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004133-25,<br>Trade Name: Afluria Quadrivalent<br>Product Name: Seqirus Quadrivalent Inactivated Influenza Vaccine (Seqirus QIV)<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ VICTORIA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Fluarix Quadrivalent<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>,Yes,NA,NA
im,EUCTR2016-004763-40-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004763-40,"<br>Trade Name: VaxigripTetra<br>Product Name: VaxigripTetra<br>Product Code: 481<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H1N1-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: mg/l milligram(s)/litre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H3N2-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Yamagata lineage)<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Victoria lineage)<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br><br>Trade Name: Vaxigrip<br>Product Name: Vaxigrip<br>Product Code: 314<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A / H1N1-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H3N2-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Victoria lineage or Yamaga",Yes,NA,NA
main,EUCTR2016-005141-23-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-005141-23,"<br>Product Name: Sparsentan<br>Product Code: RE-021<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Sparsentan<br>CAS Number: 254740-64-2<br>Current Sponsor code: RE-021<br>Other descriptive name: SPARSENTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Irbesartan tablets<br>Product Name: over-encapsulated Irbesartan Tablets<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Irbesartan<br>CAS Number: 138402-11-6<br>Other descriptive name: IRBESARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>Trade Name: Irbesartan tablets<br>Product Name: over-encapsulated Irbesartan Tablets<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Irbesartan<br>CAS Number: 138402-11-6<br>Other descriptive name: IRBESARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>",NA,NA,NA
im,EUCTR2017-001239-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001239-38,<br>Product Name: Quadrivalent VLP Influenza Vaccine<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Quadrivalent VLP Influenza Vaccine<br>Other descriptive name: INFLUENZA VACCINE<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 60-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Intramuscular use<br><br>,Yes,NA,NA
im,EUCTR2017-001270-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001270-41,<br>                Trade Name: NORADRENALINE MYLAN<br>                Product Name: NORADRENALINE MYLAN<br>                Pharmaceutical Form: Solution for infusion<br><br>                Trade Name: Dobutamine<br>                Pharmaceutical Form: Solution for infusion<br><br>,NA,NA,NA
main,EUCTR2017-002491-10-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002491-10,<br>Trade Name: Alofisel<br>Product Name: Cx601<br>Product Code: Cx601<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Darvadstrocel<br>Current Sponsor code: Allogenic eASCs<br>Other descriptive name: Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: 5000000-<br><br>,NA,Yes,NA
im,EUCTR2017-003037-28-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003037-28,<br>                Trade Name: RoActemra<br>                Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe<br>                INN or Proposed INN: TOCILIZUMAB<br>                CAS Number: 375823-41-9<br>                Other descriptive name: TOCILIZUMAB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 162-<br><br>                Trade Name: Prednisone<br>                Product Name: Prednisone<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Prednisone<br>                Current Sponsor code: Prednisone<br>                Other descriptive name: PREDNISONE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,Yes,NA
main,EUCTR2017-003342-25-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003342-25,"<br>                Trade Name: ELIQUIS 5mg<br>                Product Name: ELIQUIS 5mg<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: APIXABAN<br>                CAS Number: 503612-47-3<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br>                Pharmaceutical form of the placebo: Coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: ELIQUIS 2,5mg<br>                Product Name: ELIQUIS 2,5mg<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: APIXABAN<br>                CAS Number: 503612-47-3<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2.5-<br>                Pharmaceutical form of the placebo: Coated tablet<br>                Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2017-004026-15-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004026-15,<br>Trade Name: Feraheme®<br>Product Name: Ferumoxytol<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Ferumoxytol<br>CAS Number: 722492-56-0<br>Other descriptive name: FERUMOXYTOL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Venofer®<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: iron sucrose<br>CAS Number: 8047-67-4<br>Other descriptive name: IRON SUCROSE<br>Concentration unit: mg/l milligram(s)/litre<br>Concentration type: equal<br>Concentration number: 20-<br><br>,NA,Yes,NA
im,EUCTR2018-000005-23-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000005-23,<br>                Product Name: acylated ghrelin<br>                Product Code: G-3370-R<br>                Pharmaceutical Form: Lyophilisate for suspension for injection<br>                INN or Proposed INN: Acyl-Ghrelin<br>                CAS Number: 258279-04-8<br>                Current Sponsor code: G-3370-R<br>                Other descriptive name: GHRELIN<br>                Concentration unit: µg/ml microgram(s)/millilitre<br>                Concentration type: up to<br>                Concentration number: 600-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2018-001044-54-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001044-54,<br>                Trade Name: Bosulif<br>                Pharmaceutical Form: Tablet<br><br>                Product Name: Pegylated proline-interferon alpha 2b<br>                Product Code: AOP2014<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br><br>,NA,Yes,NA
main,EUCTR2018-001271-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001271-20,<br>                Product Code: PF-06651600<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06651600<br>                Current Sponsor code: PF-06651600<br>                Other descriptive name: PF-06651600-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: PF-06651600<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06651600<br>                Current Sponsor code: PF-06651600<br>                Other descriptive name: PF-06651600-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: PF-06700841<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06700841<br>                Current Sponsor code: PF-06700841<br>                Other descriptive name: PF-06700841-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Product Code: PF-06700841<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: PF-06700841<br>                Current Sponsor code: PF-06700841<br>                Other descriptive name: PF-06700841-15<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 25-<br><br>,NA,NA,NA
main,EUCTR2018-001671-21-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001671-21,<br>                Product Name: KRT-232<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: -<br>                Current Sponsor code: KRT-232<br>                Other descriptive name: AMG-232<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br><br>                Product Name: KRT-232<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: -<br>                Current Sponsor code: KRT-232<br>                Other descriptive name: AMG-232<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br><br>,NA,NA,NA
main,EUCTR2018-001771-21-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001771-21,<br>                Trade Name: Cabometyx™<br>                Product Name: Cabozantinib<br>                Product Code: XL184<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: CABOZANTINIB<br>                CAS Number: 1140909-48-3<br>                Current Sponsor code: XL184<br>                Other descriptive name: Cabozantinib<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Cabometyx™<br>                Product Name: Carbozantinib<br>                Product Code: XL184<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: CABOZANTINIB<br>                CAS Number: 1140909-48-3<br>                Current Sponsor code: XL184<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-002152-32-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002152-32,"<br>                Product Name: Faricimab<br>                Product Code: RO6867461/F06<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: not available<br>                CAS Number: 1607793-29-2<br>                Current Sponsor code: RO6867461<br>                Other descriptive name: VA2, VEGF-Ang2 ophtha Humanized anti-VEGF-A  anti-Ang-2 bispecific Antibody<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 120-<br><br>                Trade Name: Eylea<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: Aflibercept<br>                CAS Number: 862111-32-8<br>                Current Sponsor code: Ro 717-1571<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 40-<br><br>",NA,Yes,NA
main,EUCTR2018-002303-33-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002303-33,<br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Padsevonil<br>Product Code: UCB0942<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Padsevonil<br>CAS Number: 1294000-61-5<br>Current Sponsor code: UCB0942<br>Other descriptive name: UCB0942<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2018-002470-42-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002470-42,<br>Trade Name: Fluenz Tetra<br>Product Name: Fluenz Tetra<br>Pharmaceutical Form: Nasal spray<br>INN or Proposed INN: various influenza strains as per below<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: as above-<br><br>,NA,NA,NA
im,EUCTR2018-002876-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002876-41,<br>                Trade Name: PROPOFOL LIPURO 1%<br>                Product Name: PROPOFOL<br>                Pharmaceutical Form: Emulsion for injection/infusion<br>                Pharmaceutical form of the placebo: Emulsion for injection<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2018-003012-51-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003012-51,<br>Trade Name: TAGRISSO<br>Product Name: osimertinib<br>Product Code: AZD9291<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Osimertinib<br>CAS Number: 1421373-66-1<br>Current Sponsor code: AZD9291<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 80-<br><br>Trade Name: TAGRISSO<br>Product Name: osimertinib<br>Product Code: AZD9291<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Osimertinib<br>CAS Number: 1421373-66-1<br>Current Sponsor code: AZD9291<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br><br>Product Name: Savolitinib<br>Product Code: AZD6094<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Savolitinib<br>CAS Number: 1313725-88-0<br>Other descriptive name: SAVOLITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-200<br><br>Product Name: Savolitinib<br>Product Code: AZD6094<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Savolitinib<br>CAS Number: 1313725-88-0<br>Other descriptive name: SAVOLITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-100<br><br>,NA,NA,NA
im,EUCTR2018-003117-18-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003117-18,<br>Trade Name: Albutein 20% solución para perfusión<br>Product Name: Albúmina<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: ALBUMINA<br>CAS Number: 9006-53-5<br>Current Sponsor code: ALBUMINA<br>Other descriptive name: HUMAN SERUM ALBUMIN<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>,NA,NA,NA
main,EUCTR2018-003739-32-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003739-32,"<br>Product Name: 9-ING-41<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: 9-ING-41<br>CAS Number: 1034895-42-5<br>Other descriptive name: 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-1H-pyrrole-2,5-dione<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>",NA,NA,NA
main,EUCTR2018-004024-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004024-11,<br>Product Name: SHP648 (TAK748)<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: not applicable <br>Current Sponsor code: SHP648<br>Other descriptive name: TAK-748<br>Concentration unit: vector genomes (vg)/mL<br>Concentration type: equal<br>Concentration number: 4.1E12-<br><br>,NA,NA,NA
im,EUCTR2018-004056-37-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004056-37,<br>Product Name: Baloxavir marboxil<br>Product Code: RO7191686/F04<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: BALOXAVIR MARBOXIL<br>Current Sponsor code: RO7191686<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
main,EUCTR2018-004451-20-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004451-20,<br>                Product Name: Guselkumab<br>                Product Code: CNTO 1959<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: Guselkumab<br>                CAS Number: 1350289-85-8<br>                Current Sponsor code: CNTO 1959<br>                Other descriptive name: GUSELKUMAB<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>,NA,Yes,NA
main,EUCTR2018-004567-31-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004567-31,<br>Trade Name: CABOMETYX®<br>Product Name: Cabozantinib <br>Product Code: XL184<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: CABOZANTINIB<br>CAS Number: 1140909-48-3<br>Current Sponsor code: XL184<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: YERVOY®<br>Product Name: Ipilimumab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>Current Sponsor code: BMS-734016 MDX-010<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: OPDIVO®<br>Product Name: Nivolumab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>Current Sponsor code: BMS-936558  MDX1106  ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,Yes,NA
main,EUCTR2019-000069-19-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000069-19,<br>Trade Name: MAVENCLAD<br>Product Name: Cladribine tablets<br>Product Code: Not applicable<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
main,EUCTR2019-000119-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000119-10,<br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br><br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Suspension for oral suspension<br>INN or Proposed INN: BARICITINIB<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Humira<br>Product Name: Humira<br>Product Code: L04AB04<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ADALIMUMAB<br>CAS Number: 331731-18-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>Trade Name: Humira<br>Product Name: Humira<br>Product Code: L04AB04<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ADALIMUMAB<br>CAS Number: 331731-18-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,Yes,NA
main,EUCTR2019-000733-39-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000733-39,"<br>Product Code: ABX464<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ABX464<br>Current Sponsor code: ABX464<br>Other descriptive name: ABX464<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>",NA,NA,NA
main,EUCTR2019-001085-15-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001085-15,<br>                Trade Name: 2LHERP®<br>                Product Name: 2LHERP®<br>                Pharmaceutical Form: Pillules<br>                Pharmaceutical form of the placebo: Pillules<br>                Route of administration of the placebo: Oromucosal use<br><br>,NA,NA,NA
main,EUCTR2019-001100-38-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001100-38,<br>Product Name: BHV-3241<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Verdiperstat<br>Current Sponsor code: BHV-3241<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2019-001155-39-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001155-39,"<br>Product Name: Entrectinib<br>Product Code: RO7102122/F03<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F01<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F08<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F09<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F11<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F04<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Entrectinib<br>Product Code: RO7102122/F06<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ENTRECTINIB<br>CAS Number: 1108743-60-7<br>Current Sponsor code: RO7102122<br>Concen",NA,NA,NA
main,EUCTR2019-001222-98-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001222-98,"<br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial-COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Yervoy<br>Product Name: Ipilimumab (40ml Vial)<br>Product Code: BMS-734016<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>CAS Number: 477202-00-9<br>Current Sponsor code: BMS-734016<br>Other descriptive name: BMS734016<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Cisplatin NeoCorp 1 mg/ml - Concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Cisplatin-Ebewe, 1 mg/ml concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Cisplatin Teva® 1 mg/ml concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: CISPLATIN<br>CAS Number: 15663-27-1<br>Other descriptive name: Cisplatin<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: ETO-Cell<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ETOPOSIDE<br>CAS Number: 33419-42-0<br>Other descriptive name: ETOPOSIDE<br>Concentration unit: mg/ml mill",NA,Yes,NA
main,EUCTR2019-001458-24-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001458-24,<br>Trade Name: Onpattro<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PATISIRAN<br>CAS Number: 1386913-72-9<br>Current Sponsor code: ALN-TTR02<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2.0-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2019-001560-30-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001560-30,<br>Product Name: BAY 1747846<br>Product Code: BAY 1747846<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: BAY 1747846<br>Other descriptive name: BAY 1747846<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 193.43-<br><br>Trade Name: Gadovist<br>Product Name: Gadovist<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: gadobutrol<br>CAS Number: 138071-82-6<br>Other descriptive name: GADOBUTROL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 604.72-<br><br>,NA,NA,NA
main,EUCTR2019-001565-33-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001565-33,<br>Product Name: Zilucoplan<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Zilucoplan<br>CAS Number: 1841136-73-9<br>Current Sponsor code: RA101495<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,NA,NA
main,EUCTR2019-001854-24-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001854-24,<br>                Trade Name: Pneumovax23<br>                Product Name: Pneumovax23<br>                Pharmaceutical Form: Injection<br><br>,NA,NA,NA
main,EUCTR2019-004010-34-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004010-34,<br>Product Name: Cladribine<br>Pharmaceutical Form: Infusion<br><br>,NA,NA,NA
covid,EUCTR2020-001296-33-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001296-33,<br>Trade Name: Ilomedin<br>Product Name: Ilomedin<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: Iloprost<br>CAS Number: 78919-13-8<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
covid,EUCTR2020-001310-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38,"<br>Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI<br><br>Product Name: For example ""Gefrorenes Frischplasma / Apherese DRK Blutspendedienst""<br>Pharmaceutical Form: Solution for infusion<br><br>",NA,Yes,NA
covid,EUCTR2020-001321-31-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001321-31,<br>Trade Name: Dolquine<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Dolquine<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Kaletra versus Aluvia<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: RITONAVIR<br>CAS Number: 155213-67-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: LOPINAVIR<br>CAS Number: 192725-17-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: Imatinib<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Imatinib<br>CAS Number: 152459-95-5<br>Other descriptive name: IMATINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 400-300<br><br>Trade Name: Olumiant<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: BARICITINIB<br>Other descriptive name: Olumiant<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 4-2<br><br>,NA,Yes,NA
covid,EUCTR2020-001498-63-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001498-63,<br>Product Name: BIO101<br>Product Code: BIO101<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: NA<br>CAS Number: 5289-74-7<br>Current Sponsor code: BIO101<br>Other descriptive name: 20-hydroxyecdysone<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 175-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-001511-25-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001511-25,<br>Trade Name: COLCHICINE<br>Product Name: COLCHIMAX<br>Product Code: M04AX<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: COLCHICINA<br>CAS Number: 64-86-8<br>Other descriptive name: COLCHICINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: .5-<br><br>,NA,NA,NA
covid,EUCTR2020-001635-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001635-27,"<br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Masitinib<br>Product Code: AB1010<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Masitinib mesilate<br>CAS Number: 790299-79-5<br>Current Sponsor code: AB1010<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Isoquercetin <br>Product Code: IQC950AN <br>Pharmaceutical Form: Capsule, soft<br><br>Trade Name: Plaquenil 200 mg<br>Pharmaceutical Form: Coated tablet<br>CAS Number: 747-36-4<br>Current Sponsor code: SAR321068<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>",NA,Yes,NA
covid,EUCTR2020-001675-33-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001675-33,<br>Product Name: VPM1002<br>Pharmaceutical Form: Lyophilisate for suspension for injection<br>INN or Proposed INN: VPM1002<br>Current Sponsor code: VPM1002<br>Other descriptive name: Recombinant Mycobacterium bovis rBCG?ureC::hly; VPM1002<br>Concentration unit: CFU/ml colony forming unit(s)/millilitre<br>Concentration type: range<br>Concentration number: 2000000-8000000<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intradermal use<br><br>,NA,NA,NA
covid,EUCTR2020-001766-11-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001766-11,"<br>Trade Name: LOSARTAN ARROW 50 mg, comprimé pelliculé sécable<br>Product Name: Losartan<br>Product Code: Losartan<br>Pharmaceutical Form: Pillules<br>INN or Proposed INN: LOSARTAN<br>CAS Number: 114798-26-4<br>Current Sponsor code: losartan<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: SPIRONOLACTONE ARROW 25 mg,<br>comprimé pelliculé sécable<br>Product Name: SPIRONOLACTONE<br>Product Code: SPIRONOLACTONE<br>Pharmaceutical Form: Pillules<br>INN or Proposed INN: SPIRONOLACTONE<br>Current Sponsor code: SPIRONOLACTONE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br><br>",NA,Yes,NA
covid,EUCTR2020-001882-36-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001882-36,<br>Trade Name: Klaricid<br>Product Name: Clarithromycin<br>Pharmaceutical Form: Tablet<br><br>,NA,Yes,NA
covid,EUCTR2020-002037-15-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002037-15,<br>Trade Name: Kevzara 200 mg solution for injection in pre-filled syringe<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: SARILUMAB<br>Other descriptive name: SARILUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>,NA,Yes,NA
covid,EUCTR2020-002225-29-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002225-29,"<br>Trade Name: BERINERT<br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: C1-esterase inhibitor, human<br>Other descriptive name: C1 ESTERASE INHIBITOR (HUMAN)<br>Concentration unit: U unit(s)<br>Concentration type: equal<br>Concentration number: 2000-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: FIRAZYR<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ICATIBANT<br>CAS Number: 138614-30-9<br>Other descriptive name: ICATIBANT ACETATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>",NA,NA,NA
covid,EUCTR2020-002394-94-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002394-94,<br>Product Name: iNO<br>Pharmaceutical Form: Pressurised inhalation<br><br>,NA,NA,NA
covid,EUCTR2020-002668-29-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29,<br>Trade Name: OctaplasLG<br>Product Name: OctaplasLG<br>Pharmaceutical Form: Solution for infusion<br><br>,NA,NA,NA
covid,EUCTR2020-002728-35-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002728-35,<br>Trade Name: AVIGAN Tablets 200 mg<br>Product Name: AVIGAN<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
covid,EUCTR2020-003368-24-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24,"<br>Product Name: MK-4482<br>Product Code: MK-4482<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: MK-4482<br>CAS Number: 2349386-89-4<br>Current Sponsor code: MK-4482<br>Other descriptive name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
covid,EUCTR2020-004123-16-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004123-16,<br>Product Name: SARS-CoV-2 rS with Matrix-M1™ Adjuvant<br>Product Code: NVX-CoV2373<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: SARS-CoV-2 recombinant spike protein (SARS-CoV-2 rS) Drug Substance<br>Other descriptive name: NVX-CoV2373<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
covid,IRCT20080901001165N48,http://en.irct.ir/trial/47318,"Intervention 1: Intervention group: Syrup Zofa 10 ml every 8 hours, for 7 days. (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.",NA,NA,NA
im,IRCT20090808002306N5,http://en.irct.ir/trial/41645,Intervention 1: Control group:Patients receiving ceftriaxone + clindamycin. Intervention 2: Case group:Patients receiving  Ampicillin/Sulbactam.,NA,Yes,NA
im,IRCT20100512003915N20,http://en.irct.ir/trial/31038,"Intervention 1: Intervention group: neonates receive budesonide 0.25 mg/kg in addition to intratracheal surfactant. Intervention 2: Control group: neonates receive intratracheal surfactant 2.5 cc/kg (crusurf? Chessia, Italy).",NA,NA,NA
main,IRCT20111107008022N5,http://en.irct.ir/trial/35126,Intervention 1: Intervention group: Single dose of Metformin 750 mg tablet manufactured by Koushan Pharmed Pharmaceutical company in 24 healthy volunteers. Intervention 2: Intervention group: Single dose of Glucophage 750 mg tablet manufactured by Merck Pharmaceutical company in 24 healthy volunteers.,NA,NA,NA
main,IRCT20120215009014N308,http://en.irct.ir/trial/42604,Intervention 1: Intervention group: Transfer of frozen embryos plus an intrauterine injection of 20 ml centrifuged and activated HCG from 20 ml peripheral blood. Intervention 2: Control group: Transfer of frozen embryos alone.,NA,NA,NA
im,IRCT20130812014333N127,http://en.irct.ir/trial/39381,"Intervention 1: The intervention group, in addition to receiving one mg of epinephrine, in each respiratory resuscitation cycle, every 3 to 5 minutes later will received125 mg intravenous  methylprednisolone . Intervention 2: The intervention group, in addition to receiving one mg of epinephrine, in each respiratory resuscitation cycle, every 3 to 5 minutes later will  received 125 mg intravenous normal saline as placebo  .",NA,NA,NA
im,IRCT20130917014693N9,http://en.irct.ir/trial/40932,"Intervention 1: Intervention group: In this group the needed daily insulin calculate. This dose includes short acting insulin (Regular, Exir Company) and long action insulin (NPH, Exir Company). The patients will receive this combined dose as twice day by subcutaneous injection. This dose will be administered every morning and every evening. This protocol will be continued in all of hospitalization duration. Intervention 2: Control group: In this group, the blood glucose level of patients will be determined before each essential meals by glucometer. Then, different doses of short acting insulin (Regular, Exir Company) will be administered by subcutaneous injection. This protocol will be continued in all of hospitalization duration.",NA,NA,NA
covid,IRCT20140911019125N6,http://en.irct.ir/trial/46668,"Intervention group:  The extracted tooth is brought to the lab . After tooth extraction, it is enzymatically digested and cultured. After the cells have reached the required level, 40 million cells are injected intravenously at one time. Patients receive common medications at the same time..",NA,NA,NA
covid,IRCT20151227025726N15,http://en.irct.ir/trial/48018,Intervention 1: Intervention group: Patients in Umifenovir received Umifenovir 200 mg TDS for 7 days. Intervention 2: Control group: Patients received Lopinavir-Ritonavir 50-200 mg in 2 Tab BID for 7 days.,NA,Yes,NA
covid,IRCT20160118026097N5,http://en.irct.ir/trial/48401,"Intervention 1: ""control group:"" receiving the treatment protocol of the Ministry of Health as hydroxychloroquine sulfate tablets 200 mg or two chloroquine phosphate tablets 250 mg and kaletra tablets (lupinavir / ritonavir) 50/200 mg or tablets (atazanavir / ritonavir) 300 / 100 mg. Intervention 2: ""The intervention group:"" receiving the treatment protocol of the Ministry of Health and plasmapheresis treatment as 2 liters daily for 3 to 5 sessions (Estimated volume of plasma (in liters) = weight 0.07 x (kg) x (1 -hematocrit) and FFP replacement method 4 units, albumin 5 vials, calcium 2 ampoules, the rest of normal serum.",NA,Yes,NA
covid,IRCT20160131026298N4,http://en.irct.ir/trial/49925,"Intervention 1: Intervention group: Consumable product includes herbal syrup composed of cyclopeptide fraction with Ziziphus spina-cristi and Pimpinela anisum hydroalcoholic extract and orange peel. The dose of the product is 20 ml every 8 hours after eating, which is prepared by Herbi Pharmed Pharmaceutical Company. Intervention 2: Control group: do not use any drugs for prevention and only follow health protocols to prevent infection.",NA,NA,Yes
im,IRCT20160307026950N12,http://en.irct.ir/trial/39198,"Intervention 1: Intervention group A: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and standard monitoring devices including pulsoximetry, capnography, and electrocardiogram are attached. Patients in this group received midazolam at a dose of 1 mg/kg IV bolus. Intervention 2: Intervention group B: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and standard monitoring devices including pulsoximetry, capnography, and electrocardiogram are attached. The second group received intravenous dose of 1 mcg/kg/min of dexmedetomidine.",NA,NA,NA
covid,IRCT20160310026998N11,http://en.irct.ir/trial/46690,Intervention 1: Intervention group: in addition to standard regimen of covid-19 patients will be administered Metformin 500 mg BID  orally for 2 weeks. Intervention 2: Control group: standard regimen of covid-19 patients.,NA,NA,NA
im,IRCT2016040316473N5,http://en.irct.ir/trial/15412,Intervention 1: In intervention group: fluid resuscitation with crystalloid serum plus 100 cc albumin 20% per 1 liter of crystalloid serum. Intervention 2: In control group: fluid resuscitation only with crystalloid serum.;Treatment - Drugs;Treatment - Drugs;In intervention group: fluid resuscitation with crystalloid serum plus 100 cc albumin 20% per 1 liter of crystalloid serum.;In control group: fluid resuscitation only with crystalloid serum.,NA,NA,NA
im,IRCT2016052828134N1,http://en.irct.ir/trial/22888,"Intervention 1: intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days. Intervention 2: Control group: Using 15 ml of normal saline, every 12 hours, for 4 days.;Treatment - Drugs;Treatment - Drugs;intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days.;Control group: Using 15 ml of normal saline, every 12 hours, for 4 days.",NA,NA,NA
covid,IRCT20161206031256N3,http://en.irct.ir/trial/48329,Intervention 1: Intervention group 1: patients who will receive standard care plus 4 consecutive doses of intramuscular injection of beta-interferon (each vial contains 30 micrograms of interferon equivalent to 6 million international units. Intervention 2: Intervention group 2:  : patients who will receive standard care plus 2 doses of subcutaneous injection of Alpha-interferon (each vial contains 180 micrograms of interferon) with 7 day interval. Intervention 3: Control group 1: patients who will receive standard care plus beta-interferon placebo. Intervention 4: Control group 2: patients who will receive standard care plus alpha-interferon placebo.,NA,Yes,NA
covid,IRCT20170207032444N3,http://en.irct.ir/trial/47119,"Intervention 1: Intervention group: Tab Thalidomide ( Talidex) from Alan pharmaceuticals, daily until 14 days. Both case and control group will be received hydroxychloroquine tablet 100 mg BD, methylprednisolon 50 mg IV, antibiotic depend on physician choice (Ceftriaxone, Azithromycin, Vancomycin), Syrup Diphenhydramine and acetaminophen codeine for symptom control and amp Enoxaparin 40 mg SC daily during hospitalization. Intervention 2: Control group: this group doesnt receive extra drugs. Both groups receive tab hydroxychloroquine 200 mg BID for 5 days, Tab Acetaminophen Codeine and syrup diphenhydramine for symptom control, Antibiotics depend on physician choice (Ceftriaxone, Azithromycin, Vancomycin), Amp Enoxaparin 40 mg SC daily during hospitalization and amp Methylprednisolone 50 mg IV daily for 7 days.",NA,Yes,NA
main,IRCT20171230038142N8,http://en.irct.ir/trial/38309,"Intervention 1: Intervention group: Intervention group: 30 patients receiving St. Thomas cardiopulmonary by hand perfringens with a dose of 20 ml per kg and at a temperature of 4 degrees Celsius. This solution is surgically dispensed immediately before injection of the cardioplegia solution sterilized. Then, through a cardioplegia cannula inserted by the surgeon at the root of the aorta, it is injected through the syringe. The injection rate of the cardiopulse solution is 30 to 40 mmHg and during 2 minutes and is controlled by pressure gauge in the injection route. This solution is injected into the patient in a single dose. Intervention 2: Intervention group: Intervention group: 30 patients with cardiogenic cardiopulmonary bypass grafting by perfusion. This solution is a dose of 15 ml per kilogram and a ratio of four crystalloid units at 4 ° C and one unit of complete oxygenated blood. Both solutions are surgically dispensed sterilized immediately after injection of the cardiopulmonary solution. A cardioplegia cannula inserted by the surgeon at the root of the aorta is injected through the syringe. The injection rate of the cardiopulse solution is 30 to 40 mmHg and in the It is in 2 minutes and is controlled by pressure gauge in the injection route. This solution is injected into the patient in a single dose.",NA,NA,NA
im,IRCT20180826040877N1,http://en.irct.ir/trial/33535,"Intervention 1: Intervention group: Neonates in intervention group are first treated with Surfactant (2.5ml/kg) and 8 hours after initial dose, subsequent dose (1.25 ml/kg) is received. After receiving Surfactant, neonates in intervention group are treated with intratracheal Salbutamol (0.1 mg/kg). Intervention 2: Control group: Neonates in control group are first treated with Surfactant (2.5ml/kg) and 8 hours after initial dose, subsequent dose (1.25 ml/kg) is received. After receiving Surfactant, neonates in control group are received nothing.",NA,NA,NA
main,IRCT20180903040941N1,http://en.irct.ir/trial/33681,"Intervention 1: Intervention group: A capsule containing 500 mg of chamomile flower powder will be taken four times a day, two fasting morning and two nights before bedtime for three months. Intervention 2: Control group: placebo capsules containing roasted wheat flour plus 50 mg of chamomile powder will be taken four times a day, two fasting morning and two nights before bedtime for three months.",NA,NA,NA
covid,IRCT20180923041093N3,http://en.irct.ir/trial/46721,"Intervention 1: Intervention group: Patients in this group receive medication for treatment of Covid-19 based on Fifth Edition of the Novel Corona Virus Guidelines, in addition they recieve myrtle syrup for 5 days  (Patients daily boil the contents of a pack containing 10 grams of myrtle fruit and 10 grams of sugar in 3 glasses of water gently to stay 2 glasses, then smooth it and drink one glass in the morning and one glass in the evening.). Intervention 2: Control group: Patients in this group receive medication according to the novel Corona virus country guideline version 5.",NA,NA,NA
im,IRCT20181109041596N1,http://en.irct.ir/trial/35097,"Intervention 1: Intervention group: receivers of fluoxetine antidepressant, 20 mg daily. Intervention 2: Control group: Receivers of placebo of fluoxetine that are resemble exactly in appearance features to fluoxetine.",NA,NA,NA
main,IRCT20181207041876N1,http://en.irct.ir/trial/35752,"Intervention 1: The intervention group consumes 2 grams of Caraway powder capsules (one gram capsule after lunch and one gram capsule after a dinner)  approved by the College of Pharmacy, Kerman University of Medical Sciences for 8 weeks. Intervention 2: The control group consumes 2 grams of starch capsules (one gram capsule after lunch and one gram capsule after a dinner)  Of Shiraz Momtaz Starch Company for 8 weeks.",NA,NA,NA
main,IRCT20190122042450N3,http://en.irct.ir/trial/38419,"Intervention 1: Intervention group: Empagliflozin 10 milligram, Dr. Abidi pharmacy over 6 months. Intervention 2: Intervention group:  Pioglitazone 15 milligram, Dr. Abidi pharmacy over 6 months. Intervention 3: Control group: placebo, Dr. Abidi pharmacy over 6 months.",NA,NA,NA
main,IRCT20190410043236N1,http://en.irct.ir/trial/38837,"Intervention 1: Intervention group: Intervention group: A 50000 unit capsule of vitamin D, manufactured by Abidi company, is given weekly and at 50,000 units for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months. Intervention 2: Placebo group: Appearance of 50,000 capsules of vitamin D, manufactured by Abidi company, is given weekly for 8 weeks. It should be noted that patients will not be aware of the type of medicine. Patients are monitored for 2 months.",NA,NA,Yes
main,IRCT20190525043702N1,http://en.irct.ir/trial/39866,Intervention 1: First Intervention group: The study is split mouth and each patient will have chlorohexidine 2% in first implant. Intervention 2: Second Intervention group: The study is split mouth and each patient will have tetracycline 3% in second implant. Intervention 3: Third Intervention group: The study is split mouth and each patient will have Saliva in third implant. Intervention 4: Control group: The study is split mouth and each patient will have dry environments in control implant.,NA,Yes,NA
main,IRCT20191006044993N1,http://en.irct.ir/trial/42817,"Intervention 1: Intervention group:In the intervention group in addition to lifestyle training and in-person follow-up once every 2 weeks, the 500 mg capsule of Plantago major seed twice per day  is given, 2 capsules each time, orally for 12 weeks.The seeds of Plantago major are planted and placed in 500 mg capsules in the laboratory of the Faculty of Traditional Medicine. Intervention 2: Control group:In the intervention group in addition to lifestyle training and in-person follow-up once every 2 weeks, the 500 mg capsule of toasted flour twice per day  is given, 2 capsules each time, orally for 12 weeks.After preparation, the bread powder was placed in 500 mg capsules in the laboratory of the Faculty of Traditional Medicine.",NA,NA,Yes
covid,IRCT20200317046797N1,http://en.irct.ir/trial/46573,"Intervention 1: Intervention group: Twenty patients with Coronavirus (COVID-19)-induced pneumonia in addition to standard regimen of covid-19, will receive Camostate mesylate tablets for 3 days (200 mg three times daily). Intervention 2: Control group: they will receive standard regimen for COVID-19 patients.",NA,NA,NA
covid,IRCT20200324046850N3,http://en.irct.ir/trial/46718,"Intervention 1: Control group: Standard drugs of the national protocol (hydroxychloroquine sulfate 200mg, two single-dose tablets (Tehran Daru) , two single-dose tablets (Pars), Kaletra tablets (Lupinavir / Ritonavir) every 12 hours 2 tablets 50/200)+ A placebo every 12 hours (in terms of appearance and color similar to 500 mg naproxen). Intervention 2: Intervention Group: Standard Protocol Drugs For 5 days (Hydroxychloroquine Sulfate 200mg Two Single Dose tablets (Tehran Daroo) , Kaletra tablets (Lupinavir / Ritonavir)  every 12 hours, 2 tablets 50/200) + Naproxen 500 mg every 12 hours (Pars Daru) For 5 days.",NA,Yes,NA
covid,IRCT20200409047007N1,http://en.irct.ir/trial/47058,"Intervention 1: Intervention group: In the intervention group, patients, in addition to the current standard treatments, also receive 600 cc survivor's plasma. For the preparation of fresh plasma products, survivors with 18 to 60 years old were contacted and tested for CRP, CBC, HBS Ag, HCV Ab, HIV Ab, HTLV1 Ab, COVID 19 PCR and COVID 19 IgM & IgG antibody if they were without symptoms for at least 14 days.  If all tests are normal, 600 cc plasma will be taken from them and are prescribed to patients in less than 12 hours. Survivors should have a positive initial PCR test for coronavirus, be male, or have no history of pregnancy if they are female. The donor and the patient must be the same in blood group. Intervention 2: Control group: Patients in the control arm are selected based on information recorded in the university registry system and will be similar to the control group in terms of age, sex, underlying disease and severity of respiratory disease. In the control arm, the necessary care  and first-line therapies such as corticosteroids, antibiotics, and hydroxychloroquine will be prescribed according to the current symptoms.",NA,Yes,NA
covid,IRCT20200518047497N1,http://en.irct.ir/trial/48289,"Intervention 1: Intervention group: In the intervention group, participants will receive Laris-Hyssop distillate (including hyssop, Echium amoenum, Adiantum capillus-veneris, Hollyhocks, Eucalyptus, Malva, Platanus, chamomilla), 10 ml every 8 hours for 14 days orally. Both groups will receive routine treatments. Intervention 2: Control group: The control group will receive a placebo (no therapeutic value), resembled the Laris-Hyssop distillate with the same prescription. Both groups will receive routine treatments.",NA,NA,NA
covid,IRCT20200705048011N1,http://en.irct.ir/trial/49481,"Intervention 1: Intervention group: Recipient of garlic essential oil. Patients in the intervention group will take the drug prepared from garlic for 1 week. A drop of garlic made by Amin Pharmaceutical Company is consumed ten drops daily for a week. Each 10 drops of Garlic contains 250 grams of garlic extract. It should be noted that patients will receive routine medication for coronary artery disease. The trained nurse will perform the intervention. Intervention 2: Control group: No intervantion. Intervention 3: Intervention group: Intervention group: Recipients of cinnamon essential oil. Patients of the second intervention group will take cinnamon medicine for 1 week. Cinnamon drops made by Zardband pharmaceutical company .It will be use three times a day and 5 drops in a glass of water, tea each time. It should be noted that patients will receive routine medication for the treatment of coronary heart disease.",NA,NA,NA
covid,IRCT20201004048922N1,http://en.irct.ir/trial/51443,"Intervention 1: Intervention group: Human COVID-19 hyperimmune plasma with a specific antibody titer, volume 500ml, intravenous infusion over 4 hours; In addition to routine treatment based on the latest update of the national protocol. Intervention 2: Intervention group: Routine Human COVID-19 hyperimmune plasma, volume 500ml, intravenous infusion over 4 hours; In addition to routine treatment based on the latest update of the national protocol. Intervention 3: Control group: Routine treatment based on the latest update of the national protocol.",NA,Yes,NA
covid,IRCT20201016049048N1,http://en.irct.ir/trial/51767,Intervention 1: Intervention group: Patients in the intervention group will receive Iranian Borage Aerial Part infusion (1 g/100 cc water) TID for 5 days in addition to the routine treatment. Intervention 2: Control group: Patients in the control group will receive the placebo (100 cc boiled water) TID for 5 days in addition to the routine treatment.,NA,NA,NA
covid,ISRCTN13311119,http://isrctn.com/ISRCTN13311119,"<br>                The study consists of the following periods/assessments for participants in both the intervention and control arms.<br>                1. Screening period: -3 to -1 days. This will involve taking informed consent, assessing eligibility and comorbidity (e.g. Hypertension, Diabetes, Cardiovascular disease, etc.) through taking a medical and surgical history, smoking history, previous medication history, demographic history, physical examination, serology, 12-lead ECG, and vital signs.<br>                2. Treatment period: 0 to 14 days<br>                3. Follow-up period: 0 to 28 days. Patients will attend five study assessments at 0 (baseline assessment), 2, 8, 15 and 29 days. If nasal swabs taken at 15 days are negative participants will be invited to return 24 h later on day 16 for a second swab.<br>                4. Safety Follow-up assessment: 28 days after the last dose of the Siddha treatment was received in the event of early termination<br><br>                The patients selected for participation will be assigned randomly to one of the two treatment groups, Siddha treatment regimen + Standard of Care, or Standard of Care only, in 1:1 ratio balancing the stratification factor of co-morbidity status.<br><br>                The stratified permuted block randomization design will be used to randomize the patients in 1:1 ratio among the two treatment groups.<br><br>                Siddha treatment regimen + Standard of care will involve Siddha treatment with Kabasura kudineer and Brammanandha bairavam where indicated in addition to standard care as per local/government guidance. Kabasura kudineer will be given in the dose of 60 ml, twice a day for 7 days taken 90 minutes before food. Brammanandha bairavam will be given in the dose of 100 mg, three times a day for 7 days, ta",NA,NA,Yes
im,ISRCTN15056916,http://isrctn.com/ISRCTN15056916,"13-valent pneumococcal conjugate vaccine (PCV13) will be delivered in two schedules, one with doses scheduled at ages 6, 10 and 14 weeks (3+0 schedule) and the other with doses scheduled at ages 6 weeks and 9 months (1+1 schedule). The two schedules will be randomly allocated (1:1) to 68 geographic clusters where children attend one immunisation clinic.",Yes,NA,NA
main,ISRCTN15668391,http://isrctn.com/ISRCTN15668391,<br>                Participants are allocated by chance to receive either:<br>                1. Four oral rifampicin 300-mg capsules in addition to standard fixed-dose combination TB treatment<br>                2. Standard fixed-dose combination TB treatment<br>                Participants are followed up in hospital until the time of discharge and then as an outpatient for 12 months.<br>,NA,Yes,NA
im,ISRCTN56992547,http://isrctn.com/ISRCTN56992547,Patients are randomised into one of two groups using sealed closed opaque envelops.<br><br>Group 1: Patients receive a loading dose infusion of Dexmedetomine 1 ug/kg over 10 minutes followed by maintenance infusion of 0.5 ug/kg/h.<br><br>Group 2: Patients receive ketofol in an initial bolus dose 500 ug/kg of ketamine/propofol 1:1 followed by maintenance dose of 10 ug/kg/min.<br><br>Infusion starts for participants in both groups after admission to SICU for short term sedation of less than 12 hours. All participants are followed up until discharge from the SICU.,NA,NA,NA
covid,ISRCTN88057279,http://isrctn.com/ISRCTN88057279,"<br>                Patients will be randomised to receive either 1:1 oral hydroxychloroquine (HCQ) or standard care (no HCQ). Randomisation will be carried out using a validated bespoke automated randomisation system. Randomisation will be stratified by PROTECT sub-group, age and centre.<br><br>                Haemodialysis subgroup<br>                Dosing: 600 mg per week given as 200 mg three times per week after each haemodialysis session for 6 months<br><br>                Vasculitis and transplant subgroups<br>                Dosing: 800 mg for first 2 days followed by 400 mg once a week for 6 months<br><br>                Duration of follow up (all subgroups):<br>                Until the end of the trial, on average 6 months<br>",NA,Yes,NA
main,JPRN-JapicCTI-194635,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194635,"Intervention name : KHK4323<br>INN of the intervention : -<br>Dosage And administration of the intervention : Part 1: Single administration IV/SC, Part 2: Repeated administration IV<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Part 1: Single administration, IV/SC, Part 2: Repeated administration, IV",NA,NA,NA
main,JPRN-JapicCTI-194721,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194721,Intervention name : RO7021610<br>INN of the intervention : -<br>Dosage And administration of the intervention : RO7021610 will be administrated repeatedly by IV.<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Placebo will be administrated repeatedly by IV.,NA,NA,NA
im,JPRN-jRCT1041190001,https://jrct.niph.go.jp/latest-detail/jRCT1041190001,High-dose Corticosteroid,NA,NA,NA
main,JPRN-jRCT2031190020,https://jrct.niph.go.jp/latest-detail/jRCT2031190020,"In a 21-day-administration cycle, pevonedistat at 15 mg/m^2 (level 0: initiation dose) will be administered on days 1, 3, and 5. Oxaliplatin at 130 g/m^2 will be administered on day 1, and capecitabine will be orally administered at 2000 mg/m^2 split in 2 approximately every 12 hour for 14 days and then it was withdrawn for 7 days.",NA,NA,NA
covid,JPRN-jRCT2031200180,https://jrct.niph.go.jp/latest-detail/jRCT2031200180,"Randomized, Placebo control, Double blind comparative study",NA,NA,NA
main,JPRN-jRCT2063190013,https://jrct.niph.go.jp/latest-detail/jRCT2063190013,Ad-SGE-REIC-NS will be injected twice intra-tumorally at intervals of 14 days to  patients with recurrent malignant glioma. <br>The contrast-enhanced MRI-guided injection of Ad-SGE-REIC-NS will be done to patients undergoing burr hole surgery under local or general anesthesia by the assistance of stereotactic surgical equipment or navigation system<br>Dose will be escalated as follows:<br>   Level  1     3.0X10^10vp <br>   Level  2     1.0X10^11vp <br>   Level  3     3.0X10^11vp,NA,NA,NA
main,JPRN-jRCTs031180097,https://jrct.niph.go.jp/latest-detail/jRCTs031180097,"Arm A: modified PETHEMA-MPB therapy consists of nine cycles: one cycle of subcutaneous or intravenous bortezomib given twice per week for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus oral melphalan 9 mg/m2 and oral prednisolone 60 mg/m2 on days 1-4, followed by eight cycles of subcutaneous or intravenous bortezomib once per week for 5 weeks (1.3 mg/m2 on days 1, 8, 15, and 22) plus the same doses of oral melphalan and prednisolone.<br>Arm B: JCOG-MPB therapy consists of nine cycles of subcutaneous or intravenous bortezomib give once per week for 4 weeks (1.3 mg/m2 on days 1, 8 and 15), plus oral melphalan 7 mg/m2 and oral prednisolone 60 mg/m2 on days 1-4.",NA,NA,NA
main,JPRN-jRCTs031180139,https://jrct.niph.go.jp/latest-detail/jRCTs031180139,"A: R-CHOP (tri-weekly rituximab plus CHOP), 8 cycles<br>Cyclophosphamide 750 mg/m2, day 1<br>Doxorubicin 50 mg/m2, day 1<br>Vincristine 1.4 mg/m2 (max 2.0 mg/body), day 1<br>Prednisolone 100 mg/body, day 1-5<br>Rituximab 375 mg/m2, day 1<br>B: RW+CHOP (weekly rituximab plus CHOP) , 8 cycles<br>Cyclophosphamide 750 mg/m2, day 1<br>Doxorubicin 50 mg/m2, day 1<br>Vincristine 1.4 mg/m2 (max 2.0 mg/body), day 1<br>Prednisolone 100 mg/body, day 1-5<br>Rituximab 375 mg/m2, day 1,8,15,22,29,36,43,50",NA,Yes,NA
main,JPRN-jRCTs031180183,https://jrct.niph.go.jp/latest-detail/jRCTs031180183,Disulfiram (po): 160mg three times daily (480mg/day) or 80mg three times daily (240mg/day) for maximum 6 cycles.<br>Nivolumab (iv): 240mg every 2 weeks for maximum 6 cycles.<br>1 cycle is for 28 days.,NA,Yes,NA
im,JPRN-jRCTs031190084,https://jrct.niph.go.jp/latest-detail/jRCTs031190084,"Atezolizumab 1200mg, every 3 weeks",NA,Yes,NA
im,JPRN-jRCTs041180086,https://jrct.niph.go.jp/latest-detail/jRCTs041180086,using orexin receptor antagonist Suvorexant,NA,NA,NA
main,JPRN-jRCTs051180199,https://jrct.niph.go.jp/latest-detail/jRCTs051180199,Anti-cancer drug administration,NA,NA,NA
covid,JPRN-jRCTs051200036,https://jrct.niph.go.jp/latest-detail/jRCTs051200036,Administration of nintedanib via nasogastric tube,NA,NA,NA
im,JPRN-UMIN000023355,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025429,"administration of clarithromycin, 200mg/day, 1 year<br>control",NA,Yes,NA
im,JPRN-UMIN000026129,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029759,"Nivolumab 3mg/kg, every 2 weeks",NA,Yes,NA
im,JPRN-UMIN000031793,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036145,Sodium glucose cotransporter 2inhibitor,NA,NA,NA
im,JPRN-UMIN000035028,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039927,Baloxavir marboxil<br>Oseltamivir<br>Laninamivir,NA,Yes,NA
main,JPRN-UMIN000035965,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040963,Goreisan,NA,NA,NA
main,JPRN-UMIN000037291,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042438,Luseogliflozin<br>Standard Therapy without Luseogliflozin,NA,NA,NA
main,KCT0003909,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=13801,Drug : Osimertinib 80mg once daily po every 6 weeks (=1 cycle),NA,NA,NA
main,KCT0004211,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14441,"Drug : If a cardiac and cardiovascular surgery is carried out in the same way as a conventional surgery and it is determined that there are no more bleeding areas, the assigned test drug is applied around the heart and the surgery is terminated. The test drug is assigned and applied to clinical subjects, divided into one to one placebo group and one to one for the Tranexamatic acid low dose group (1g) and two to one for the high dose group (2.5g) according to a random assignment table.",NA,NA,NA
im,NCT02691130,https://clinicaltrials.gov/show/NCT02691130,Biological: Multimeric 001 (M-001);Biological: H5N1 influenza vaccine;Biological: Saline,Yes,NA,NA
im,NCT02708173,https://clinicaltrials.gov/show/NCT02708173,Biological: One dose of Quadrivalent Influenza Virus Vaccine;Biological: One dose of Quadrivalent Influenza Virus Vaccine,Yes,NA,NA
im,NCT02719743,https://clinicaltrials.gov/show/NCT02719743,Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).;Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).;Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).,Yes,NA,NA
im,NCT02739568,https://clinicaltrials.gov/show/NCT02739568,Drug: Pitolisant (BF2.649);Drug: Placebo,NA,NA,NA
im,NCT02774044,https://clinicaltrials.gov/show/NCT02774044,Drug: Cadisurf;Drug: Survanta,NA,NA,NA
im,NCT02809209,https://clinicaltrials.gov/show/NCT02809209,Biological: IVACFLU-S;Biological: Placebo,NA,NA,NA
im,NCT02831608,https://clinicaltrials.gov/show/NCT02831608,Biological: Influenza vaccine;Biological: Placebo,Yes,NA,NA
im,NCT02836340,https://clinicaltrials.gov/show/NCT02836340,Drug: 2-Iminobiotin;Drug: 2-Iminobiotin;Drug: 2-Iminobiotin,NA,NA,NA
im,NCT02853929,https://clinicaltrials.gov/show/NCT02853929,Biological: Infanrix hexa,NA,NA,NA
im,NCT02903836,https://clinicaltrials.gov/show/NCT02903836,Drug: Nafithromycin 800 mg 3 days;Drug: Nafithromycin 800 mg 5 days;Drug: Moxifloxacin 400 mg,NA,Yes,NA
im,NCT02987374,https://clinicaltrials.gov/show/NCT02987374,Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM),Yes,NA,NA
im,NCT03020498,https://clinicaltrials.gov/show/NCT03020498,Biological: Fluzone;Biological: FluMist;Biological: Fluzone;Biological: FluMist;Biological: Fluzone;Biological: FluMist,Yes,NA,NA
im,NCT03020537,https://clinicaltrials.gov/show/NCT03020537,Biological: Fluzone;Biological: Fluzone;Biological: Fluzone,Yes,NA,NA
im,NCT03027609,https://clinicaltrials.gov/show/NCT03027609,Drug: AR-105;Drug: placebo,NA,NA,NA
im,NCT03068741,https://clinicaltrials.gov/show/NCT03068741,Drug: Comparison 1: Prehospital Ceftriaxone;Drug: Comparison 1: Placebo;Drug: Comparison 2: Liberal fluids;Drug: Comparison 2: Conservative fluids,NA,NA,NA
im,NCT03122639,https://clinicaltrials.gov/show/NCT03122639,Drug: Atorvastatin 10mg;Drug: Placebo,NA,NA,NA
im,NCT03143101,https://clinicaltrials.gov/show/NCT03143101,Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation,NA,NA,NA
im,NCT03160118,https://clinicaltrials.gov/show/NCT03160118,"Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine",Yes,NA,NA
im,NCT03186742,https://clinicaltrials.gov/show/NCT03186742,Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab,NA,NA,NA
im,NCT03202394,https://clinicaltrials.gov/show/NCT03202394,Drug: BIO-11006;Drug: Placebo,NA,NA,NA
im,NCT03208101,https://clinicaltrials.gov/show/NCT03208101,Biological: DTP-HepB-IPV-Hib vaccine;Biological: DTP-HepB-Hib vaccine & IPV,Yes,NA,NA
im,NCT03208361,https://clinicaltrials.gov/show/NCT03208361,Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin,NA,NA,NA
im,NCT03235986,https://clinicaltrials.gov/show/NCT03235986,Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I);Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II);Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I);Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II),NA,NA,NA
im,NCT03275415,https://clinicaltrials.gov/show/NCT03275415,Drug: budesonide;Drug: Saline,NA,NA,NA
im,NCT03282240,https://clinicaltrials.gov/show/NCT03282240,Biological: QIV-HD;Biological: Licensed TIV-HD1;Biological: Investigational TIV-HD2,NA,NA,NA
im,NCT03330132,https://clinicaltrials.gov/show/NCT03330132,Biological: Standard inactivated influenza vaccine (NH formulation);Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation);Biological: High-dose inactivated influenza vaccine (NH formulation);Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation),Yes,NA,NA
im,NCT03336619,https://clinicaltrials.gov/show/NCT03336619,Drug: Nitazoxanide;Drug: Placebo,NA,NA,NA
im,NCT03337373,https://clinicaltrials.gov/show/NCT03337373,Drug: cisatracurium,NA,NA,NA
im,NCT03345992,https://clinicaltrials.gov/show/NCT03345992,Drug: Clarithromycin;Drug: Water for injection,NA,Yes,NA
im,NCT03380507,https://clinicaltrials.gov/show/NCT03380507,Drug: Triple therapy group,NA,NA,NA
im,NCT03383887,https://clinicaltrials.gov/show/NCT03383887,Drug: Placebo oral capsule;Drug: DAW1033D oral capsule,NA,NA,NA
im,NCT03441373,https://clinicaltrials.gov/show/NCT03441373,Drug: XC8 20 mg;Drug: XC8 100 mg;Drug: XC8 200 mg;Drug: Placebo,NA,NA,NA
im,NCT03450915,https://clinicaltrials.gov/show/NCT03450915,Biological: M-001;Biological: Saline,NA,NA,NA
im,NCT03453801,https://clinicaltrials.gov/show/NCT03453801,Biological: Fluzone®;Biological: FluMist®,Yes,NA,NA
im,NCT03454217,https://clinicaltrials.gov/show/NCT03454217,Drug: Oxycodone;Drug: Tramadol,NA,NA,NA
im,NCT03459391,https://clinicaltrials.gov/show/NCT03459391,Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo;Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo;Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo,NA,NA,NA
im,NCT03489018,https://clinicaltrials.gov/show/NCT03489018,Biological: PCV10;Biological: PCV13,NA,NA,NA
im,NCT03530124,https://clinicaltrials.gov/show/NCT03530124,Biological: PCV13;Biological: DTaP;Biological: HBV;Biological: IPV;Biological: Hib,NA,NA,NA
im,NCT03567577,https://clinicaltrials.gov/show/NCT03567577,Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation;Drug: 0.9% Saline Solution,NA,NA,NA
im,NCT03581903,https://clinicaltrials.gov/show/NCT03581903,Biological: H7N3 pLAIV;Biological: H7N9 pIIV,NA,NA,NA
im,NCT03592277,https://clinicaltrials.gov/show/NCT03592277,Drug: Vitamin C;Drug: Vitamin B1,NA,NA,Yes
im,NCT03607071,https://clinicaltrials.gov/show/NCT03607071,Drug: Prednisolone and taper,NA,NA,NA
im,NCT03608514,https://clinicaltrials.gov/show/NCT03608514,Drug: Experimental,NA,NA,NA
im,NCT03614975,https://clinicaltrials.gov/show/NCT03614975,Biological: Flucelvax inactivated influenza vaccine;Biological: Fluzone inactivated influenza vaccine,Yes,NA,NA
im,NCT03640052,https://clinicaltrials.gov/show/NCT03640052,Drug: Placebo oral capsule;Drug: LTM1201L;Drug: LTM1201LN;Drug: LTM1201LB;Drug: LTM1201LD,NA,NA,NA
im,NCT03651557,https://clinicaltrials.gov/show/NCT03651557,Drug: Neu2000KWL High-dose group;Drug: Neu2000KWL Low-dose group;Drug: Placebo,NA,NA,NA
im,NCT03657719,https://clinicaltrials.gov/show/NCT03657719,Biological: GC3114;Biological: GCFLU Quadrivalent,NA,NA,NA
im,NCT03690583,https://clinicaltrials.gov/show/NCT03690583,Drug: Zinc sulfate;Other: Glucose;Drug: Zinc sulfate;Other: Glucose,NA,NA,NA
im,NCT03694808,https://clinicaltrials.gov/show/NCT03694808,Drug: Fluad Vaccine;Drug: Fluzone HD Vaccine,Yes,NA,NA
im,NCT03773822,https://clinicaltrials.gov/show/NCT03773822,Combination Product: Hydrocortisone + Flucortac;Other: Placebo,NA,NA,NA
im,NCT03782259,https://clinicaltrials.gov/show/NCT03782259,Drug: dapagliflozin;Other: Placebo,NA,NA,NA
main,NCT03803540,https://clinicaltrials.gov/show/NCT03803540,Other: Fecal Microbiota Transplantation,NA,NA,NA
main,NCT03805568,https://clinicaltrials.gov/show/NCT03805568,Drug: dexmedetomidine infusion group;Drug: remifentanil infusion group,NA,NA,NA
main,NCT03813121,https://clinicaltrials.gov/show/NCT03813121,Drug: midazolam intravenous infusion;Drug: placebo intravenous infusion;Drug: ketamine intravenous infusion,NA,NA,NA
main,NCT03815929,https://clinicaltrials.gov/show/NCT03815929,Drug: Estradiol 100 Micrograms Patch;Drug: Estradiol Patch,NA,NA,NA
im,NCT03816878,https://clinicaltrials.gov/show/NCT03816878,Biological: H5N1 pISV,NA,NA,NA
main,NCT03829332,https://clinicaltrials.gov/show/NCT03829332,Biological: Pembrolizumab;Drug: Lenvatinib;Drug: Placebo for lenvatinib,NA,Yes,NA
main,NCT03835949,https://clinicaltrials.gov/show/NCT03835949,Drug: TJ004309;Drug: Atezolizumab,NA,Yes,NA
main,NCT03841110,https://clinicaltrials.gov/show/NCT03841110,Drug: FT500;Drug: Nivolumab;Drug: Pembrolizumab;Drug: Atezolizumab;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: IL-2,NA,Yes,NA
im,NCT03845231,https://clinicaltrials.gov/show/NCT03845231,Biological: Flucelvax(R);Other: Human Challenge virus,NA,NA,NA
main,NCT03856164,https://clinicaltrials.gov/show/NCT03856164,Drug: Tranexamic Acid;Drug: Placebo,NA,NA,NA
main,NCT03862807,https://clinicaltrials.gov/show/NCT03862807,Drug: Patisiran,NA,NA,NA
main,NCT03863938,https://clinicaltrials.gov/show/NCT03863938,Drug: Tegoprazan 50mg,NA,NA,NA
main,NCT03868423,https://clinicaltrials.gov/show/NCT03868423,Drug: Brigatinib;Other: Laboratory Biomarker Analysis;Other: Quality-of-Life Assessment;Other: Questionnaire Administration,NA,NA,NA
main,NCT03876210,https://clinicaltrials.gov/show/NCT03876210,"Combination Product: PK101;Drug: PK101-001, PK101-002",NA,NA,NA
main,NCT03884465,https://clinicaltrials.gov/show/NCT03884465,Drug: Inhaled dry powder treprostinil (LIQ861),NA,NA,NA
main,NCT03896685,https://clinicaltrials.gov/show/NCT03896685,"Drug: Bedaquiline 100 MG;Drug: Delamanid 50 MG Oral Tablet;Drug: Clofazimine Pill;Drug: Linezolid Pill;Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines",NA,NA,NA
im,NCT03898973,https://clinicaltrials.gov/show/NCT03898973,Biological: Quadrivalent inactivated influenza vaccine (IIV),Yes,NA,NA
im,NCT03900988,https://clinicaltrials.gov/show/NCT03900988,Drug: N-acetyl cysteine;Drug: 5% Dextrose,NA,NA,NA
main,NCT03904199,https://clinicaltrials.gov/show/NCT03904199,Drug: Insulin,NA,NA,NA
main,NCT03904836,https://clinicaltrials.gov/show/NCT03904836,Drug: Tobramycin,NA,Yes,NA
main,NCT03905109,https://clinicaltrials.gov/show/NCT03905109,Drug: ABX464;Drug: Placebo,NA,NA,NA
im,NCT03911440,https://clinicaltrials.gov/show/NCT03911440,Drug: Doxycycline;Drug: Azithromycin,NA,Yes,NA
im,NCT03911817,https://clinicaltrials.gov/show/NCT03911817,Drug: Midodrine,NA,NA,NA
main,NCT03913130,https://clinicaltrials.gov/show/NCT03913130,Drug: QR-110,NA,NA,NA
main,NCT03913559,https://clinicaltrials.gov/show/NCT03913559,Drug: Inotuzumab ozogamicin;Drug: Methotrexate;Drug: Hydrocortisone;Drug: Cytarabine;Drug: Diphenhydramine;Drug: Acetaminophen;Drug: Methylprednisolone,NA,Yes,NA
main,NCT03915366,https://clinicaltrials.gov/show/NCT03915366,Drug: Valganciclovir Oral Solution [Valcyte];Drug: Tuberculostatic Agents,NA,Yes,NA
main,NCT03926377,https://clinicaltrials.gov/show/NCT03926377,Procedure: bone densitometry;Biological: blood test;Procedure: radiographs of the thoracic and lumbar spine;Procedure: Clobetasol propionate,NA,NA,NA
main,NCT03927781,https://clinicaltrials.gov/show/NCT03927781,Drug: Pregabalin 300mg,NA,NA,NA
main,NCT03931135,https://clinicaltrials.gov/show/NCT03931135,Drug: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section,NA,Yes,NA
main,NCT03958097,https://clinicaltrials.gov/show/NCT03958097,Combination Product: NK cell and PD-1 antibody,NA,NA,NA
im,NCT03958396,https://clinicaltrials.gov/show/NCT03958396,Drug: Remifentanil Infusion,NA,NA,NA
main,NCT03961308,https://clinicaltrials.gov/show/NCT03961308,Drug: Vedolizumab SC,NA,Yes,NA
main,NCT03961334,https://clinicaltrials.gov/show/NCT03961334,Drug: Dabigatran;Drug: Apixaban;Drug: Edoxaban;Drug: Aspirin;Drug: Clopidogrel,NA,NA,NA
main,NCT03966170,https://clinicaltrials.gov/show/NCT03966170,Drug: Citicoline;Drug: Placebo oral tablet,NA,NA,NA
im,NCT03968640,https://clinicaltrials.gov/show/NCT03968640,Dietary Supplement: CoQ10;Dietary Supplement: Placebo,NA,NA,NA
main,NCT03973177,https://clinicaltrials.gov/show/NCT03973177,Drug: Phenol Injection;Drug: Methylprednisolone Injection,NA,NA,NA
main,NCT03985995,https://clinicaltrials.gov/show/NCT03985995,Drug: CBD 800 mg p.o;Drug: Placebo p.o,NA,NA,NA
main,NCT03991520,https://clinicaltrials.gov/show/NCT03991520,Drug: Anakinra 100Mg/0.67Ml Inj Syringe;Drug: Placebo,NA,NA,NA
main,NCT03993379,https://clinicaltrials.gov/show/NCT03993379,Drug: CX-072;Drug: Ipilimumab,NA,Yes,NA
main,NCT03998085,https://clinicaltrials.gov/show/NCT03998085,Drug: Anlotinib Hydrochloride,NA,NA,NA
main,NCT04003688,https://clinicaltrials.gov/show/NCT04003688,Drug: Magnesium sulfate through real weight group;Drug: Placebo group;Drug: Magnesium sulfate through ideal corrected weight group,NA,Yes,NA
main,NCT04014556,https://clinicaltrials.gov/show/NCT04014556,Device: micropulse laser;Drug: Aflibercept,NA,NA,NA
im,NCT04016246,https://clinicaltrials.gov/show/NCT04016246,Drug: Propofol-Lipuro;Drug: Placebos,NA,NA,NA
main,NCT04019704,https://clinicaltrials.gov/show/NCT04019704,Drug: AXS-05;Drug: Placebo,NA,NA,NA
im,NCT04020003,https://clinicaltrials.gov/show/NCT04020003,Drug: Levosimendan,NA,NA,NA
im,NCT04020263,https://clinicaltrials.gov/show/NCT04020263,Drug: Levosimendan 2.5 MG/ML Injectable Solution;Drug: Placebo,NA,NA,NA
im,NCT04023305,https://clinicaltrials.gov/show/NCT04023305,Drug: Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts,NA,NA,NA
main,NCT04026438,https://clinicaltrials.gov/show/NCT04026438,Drug: Potassium Phosphate Injection,NA,NA,NA
main,NCT04032171,https://clinicaltrials.gov/show/NCT04032171,Drug: Evobrutinib;Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo;Drug: Placebo,NA,NA,NA
main,NCT04049669,https://clinicaltrials.gov/show/NCT04049669,Drug: Indoximod;Radiation: Partial Radiation;Radiation: Full-dose Radiation;Drug: Indoximod;Drug: Temozolomide;Drug: Cyclophosphamide;Drug: Etoposide;Drug: Lomustine,NA,NA,NA
main,NCT04061590,https://clinicaltrials.gov/show/NCT04061590,Drug: Cisplatin;Biological: Pembrolizumab;Drug: Pemetrexed;Drug: Pemetrexed Disodium;Procedure: Therapeutic Conventional Surgery,NA,Yes,NA
main,NCT04061876,https://clinicaltrials.gov/show/NCT04061876,Drug: Ruxolitinib;Drug: Corticosteroid,NA,NA,NA
main,NCT04063267,https://clinicaltrials.gov/show/NCT04063267,Device: E cigarettes;Other: Nicotine Replacement Therapy,NA,NA,NA
main,NCT04078386,https://clinicaltrials.gov/show/NCT04078386,Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg,NA,NA,NA
main,NCT04082325,https://clinicaltrials.gov/show/NCT04082325,Drug: Lu AF88434;Drug: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434);Drug: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434);Drug: Placebo,NA,NA,NA
main,NCT04082910,https://clinicaltrials.gov/show/NCT04082910,Drug: Metoprolol;Drug: anti-TNFa antibody,NA,NA,NA
im,NCT04094857,https://clinicaltrials.gov/show/NCT04094857,Drug: HBN-1,NA,NA,NA
main,NCT04095936,https://clinicaltrials.gov/show/NCT04095936,Drug: Romiplostim,NA,NA,NA
main,NCT04096911,https://clinicaltrials.gov/show/NCT04096911,Drug: Sintilimab;Drug: quadrivalent HPV vaccine,Yes,Yes,NA
main,NCT04097080,https://clinicaltrials.gov/show/NCT04097080,Drug: NBTX-001;Drug: Standard of Care,NA,NA,NA
main,NCT04114747,https://clinicaltrials.gov/show/NCT04114747,Other: Starting at high or low blood pressure,NA,NA,NA
main,NCT04121039,https://clinicaltrials.gov/show/NCT04121039,Drug: Apatinib;Drug: POF,NA,NA,NA
main,NCT04126811,https://clinicaltrials.gov/show/NCT04126811,"Drug: Apatinib Mesylate, Pirarubicin, Ifosfamide;Drug: Apatinib Mesylate;Drug: Pirarubicin, Ifosfamide",NA,Yes,NA
im,NCT04130230,https://clinicaltrials.gov/show/NCT04130230,Drug: Neostigmine;Drug: Standard therapy,NA,NA,NA
im,NCT04137887,https://clinicaltrials.gov/show/NCT04137887,"Biological: Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD);Biological: Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)",Yes,NA,NA
main,NCT04144192,https://clinicaltrials.gov/show/NCT04144192,Drug: Lidocaine patch 1.8%;Drug: Lidocaine 5% patch;Drug: Lidocaine 2% Injectable Solution,NA,Yes,NA
im,NCT04146623,https://clinicaltrials.gov/show/NCT04146623,Biological: CodaVax-H1N1 influenza vaccine;Biological: Normal Saline Placebo,Yes,NA,NA
im,NCT04160260,https://clinicaltrials.gov/show/NCT04160260,Drug: Omadacycline,NA,NA,NA
main,NCT04170023,https://clinicaltrials.gov/show/NCT04170023,Drug: ALXN2050;Drug: C5 inhibitor background therapy,NA,NA,NA
im,NCT04198883,https://clinicaltrials.gov/show/NCT04198883,Combination Product: Protheracytes,NA,NA,NA
main,NCT04209959,https://clinicaltrials.gov/show/NCT04209959,Drug: nifekalant,NA,NA,NA
covid,NCT04282902,https://clinicaltrials.gov/show/NCT04282902,Drug: pirfenidone,NA,NA,NA
covid,NCT04293887,https://clinicaltrials.gov/show/NCT04293887,Drug: Recombinant human interferon a1ß,NA,Yes,NA
covid,NCT04325061,https://clinicaltrials.gov/show/NCT04325061,Drug: Dexamethasone,NA,Yes,NA
covid,NCT04333472,https://clinicaltrials.gov/show/NCT04333472,Drug: Piclidenoson;Drug: Placebo,NA,NA,NA
covid,NCT04334005,https://clinicaltrials.gov/show/NCT04334005,Dietary Supplement: Vitamin D,NA,NA,Yes
covid,NCT04334148,https://clinicaltrials.gov/show/NCT04334148,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04342728,https://clinicaltrials.gov/show/NCT04342728,Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care,NA,NA,NA
covid,NCT04342897,https://clinicaltrials.gov/show/NCT04342897,Drug: LY3127804;Drug: Placebo,NA,NA,NA
covid,NCT04343092,https://clinicaltrials.gov/show/NCT04343092,Drug: Ivermectin (IVM),NA,NA,NA
covid,NCT04345861,https://clinicaltrials.gov/show/NCT04345861,Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin,NA,Yes,NA
covid,NCT04346329,https://clinicaltrials.gov/show/NCT04346329,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04347239,https://clinicaltrials.gov/show/NCT04347239,Drug: Placebos;Drug: Leronlimab (700mg),NA,Yes,NA
covid,NCT04348409,https://clinicaltrials.gov/show/NCT04348409,Drug: Nitazoxanide Tablets;Drug: Placebo,NA,NA,NA
covid,NCT04350580,https://clinicaltrials.gov/show/NCT04350580,Drug: Human immunoglobulin;Drug: Placebo,NA,NA,NA
covid,NCT04356690,https://clinicaltrials.gov/show/NCT04356690,Drug: Etoposide,NA,NA,NA
covid,NCT04361214,https://clinicaltrials.gov/show/NCT04361214,Drug: Leflunomide,NA,NA,NA
covid,NCT04362189,https://clinicaltrials.gov/show/NCT04362189,Drug: HB-adMSC;Drug: Placebo,NA,NA,NA
covid,NCT04365309,https://clinicaltrials.gov/show/NCT04365309,Drug: Aspirin 100mg,NA,NA,NA
covid,NCT04366063,https://clinicaltrials.gov/show/NCT04366063,Biological: Cell therapy protocol 1;Biological: Cell therapy protocol 2,NA,NA,NA
covid,NCT04366908,https://clinicaltrials.gov/show/NCT04366908,Drug: BAT + Calcifediol;Drug: BAT,NA,NA,NA
covid,NCT04372186,https://clinicaltrials.gov/show/NCT04372186,Drug: Placebo;Drug: Tocilizumab,NA,Yes,NA
covid,NCT04380376,https://clinicaltrials.gov/show/NCT04380376,Drug: Melphalan;Other: Standard of care,NA,NA,NA
covid,NCT04380519,https://clinicaltrials.gov/show/NCT04380519,Biological: RPH-104 80 mg;Drug: Olokizumab 64 mg;Drug: Placebo,NA,Yes,NA
covid,NCT04382586,https://clinicaltrials.gov/show/NCT04382586,Drug: Zanubrutinib;Drug: Supportive Care;Drug: Placebo,NA,NA,NA
covid,NCT04390178,https://clinicaltrials.gov/show/NCT04390178,Biological: SARS-CoV-2 convalescent plasma,NA,Yes,NA
covid,NCT04394377,https://clinicaltrials.gov/show/NCT04394377,Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed;Drug: Group 2: control group with enoxaparin 40mg/d,NA,Yes,NA
covid,NCT04397562,https://clinicaltrials.gov/show/NCT04397562,Drug: Levilimab;Drug: Placebo,NA,Yes,NA
covid,NCT04409262,https://clinicaltrials.gov/show/NCT04409262,Drug: Remdesivir;Drug: Tocilizumab;Drug: Placebo,NA,Yes,NA
covid,NCT04412018,https://clinicaltrials.gov/show/NCT04412018,Drug: Icosapent ethyl,NA,NA,NA
covid,NCT04419623,https://clinicaltrials.gov/show/NCT04419623,Drug: Part 1 - TL-895;Drug: Part 2 - TL-895;Drug: Part 2 - Placebo,NA,NA,NA
covid,NCT04423861,https://clinicaltrials.gov/show/NCT04423861,Drug: Nitazoxanide;Drug: Placebo,NA,NA,NA
covid,NCT04432324,https://clinicaltrials.gov/show/NCT04432324,Biological: Intravenous Immune Globulin;Drug: Standard Medical Treatment,NA,NA,NA
covid,NCT04436458,https://clinicaltrials.gov/show/NCT04436458,Drug: Niclosamide Oral Tablet;Drug: Placebo,NA,NA,NA
covid,NCT04442048,https://clinicaltrials.gov/show/NCT04442048,Biological: IMM-101;Other: Observation,NA,NA,NA
covid,NCT04446377,https://clinicaltrials.gov/show/NCT04446377,Drug: Apilimod Dimesylate Capsule;Other: Placebo,NA,NA,NA
covid,NCT04447235,https://clinicaltrials.gov/show/NCT04447235,Drug: Placebo;Drug: Ivermectin;Drug: Losartan,NA,NA,NA
covid,NCT04452669,https://clinicaltrials.gov/show/NCT04452669,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),NA,NA,NA
covid,NCT04454307,https://clinicaltrials.gov/show/NCT04454307,Drug: Tramadol;Other: Standard care delivered in the isolation hospitals.,NA,NA,NA
covid,NCT04455815,https://clinicaltrials.gov/show/NCT04455815,Drug: Camostat,NA,NA,NA
covid,NCT04460651,https://clinicaltrials.gov/show/NCT04460651,Drug: Icosapent ethyl (IPE);Drug: Placebo,NA,NA,NA
covid,NCT04466280,https://clinicaltrials.gov/show/NCT04466280,Drug: Hydroxychloroquine;Drug: Mucodentol;Device: Personal protective equipment,NA,Yes,NA
covid,NCT04466540,https://clinicaltrials.gov/show/NCT04466540,Drug: Hydroxychloroquine;Drug: Placebo,NA,Yes,NA
covid,NCT04468009,https://clinicaltrials.gov/show/NCT04468009,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04470531,https://clinicaltrials.gov/show/NCT04470531,Drug: oral co-trimoxazole,NA,NA,NA
covid,NCT04483830,https://clinicaltrials.gov/show/NCT04483830,Drug: Sulodexide;Drug: Placebo,NA,NA,NA
covid,NCT04487886,https://clinicaltrials.gov/show/NCT04487886,Drug: Duvelisib;Drug: Placebo,NA,NA,NA
covid,NCT04491994,https://clinicaltrials.gov/show/NCT04491994,Drug: HCQ,NA,NA,NA
covid,NCT04494399,https://clinicaltrials.gov/show/NCT04494399,Drug: Interferon beta-1b;Drug: Ribavirin,NA,Yes,NA
covid,NCT04494724,https://clinicaltrials.gov/show/NCT04494724,Drug: Clazakizumab;Drug: Placebo,NA,Yes,NA
covid,NCT04498936,https://clinicaltrials.gov/show/NCT04498936,Drug: Sofosbuvir and Ledipasvir;Drug: Nitazoxanide,NA,Yes,NA
covid,NCT04527081,https://clinicaltrials.gov/show/NCT04527081,Biological: AG0302-COVID19;Biological: AG0302-COVID19;Biological: AG0302-COVID19,NA,NA,NA
covid,NCT04535856,https://clinicaltrials.gov/show/NCT04535856,Drug: allogeneic mesenchymal stem cell;Other: Placebo,NA,Yes,NA
covid,NCT04540120,https://clinicaltrials.gov/show/NCT04540120,Drug: dapansutrile capsules;Drug: placebo capsules,NA,NA,NA
covid,NCT04541979,https://clinicaltrials.gov/show/NCT04541979,Drug: aerosolized DNase;Drug: NaCl,NA,NA,NA
covid,NCT04549376,https://clinicaltrials.gov/show/NCT04549376,Drug: Povidone-Iodine 0.4% NI;Drug: Povidone-Iodine 0.5% NI;Drug: Povidone-Iodine 0.6% NI;Drug: Povidone-Iodine 0.5% NS;Drug: Povidone-Iodine 0.6% NS;Other: Placebo comparator: DW-NI;Other: Placebo comparator: DW-NS,NA,NA,NA
covid,NCT04555148,https://clinicaltrials.gov/show/NCT04555148,Biological: GC5131;Other: Placebo,NA,NA,NA
covid,NCT04563702,https://clinicaltrials.gov/show/NCT04563702,Biological: VXA-CoV2-1,NA,NA,NA
covid,NCT04564716,https://clinicaltrials.gov/show/NCT04564716,Biological: Gam-COVID-Vac;Other: Placebo,NA,NA,NA
covid,NCT04565249,https://clinicaltrials.gov/show/NCT04565249,Drug: PLN-74809;Drug: Placebo,NA,NA,NA
covid,NCT04575597,https://clinicaltrials.gov/show/NCT04575597,Drug: Molnupiravir;Drug: Placebo,NA,Yes,NA
covid,NL8547,https://trialregister.nl/trial/8547,BCG-vaccine,Yes,NA,NA
main,PACTR201908793583382,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8297,;tranexamic acid group;carbetocin group,NA,Yes,NA
covid,PACTR202006760881890,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168,;Convalescent Plasma;Normal saline,NA,Yes,NA
im,PER-016-17,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=016-17,"Delafloxacin 300 mg will be administered as a 1-hour IV infusion every 12 hours (± 2 hours) for a minimum of 6 doses with an option to switch to delafloxacin 450 mg tablet administered orally every 12 hours (± 2 hours) for the remaining doses. <br>Moxifloxacin 400 mg will be administered as a 1-hour IV infusion every 24 (± 2 hours) hours for a minimum of 3 active doses with an option to switch to moxifloxacin 400 mg (over-encapsulated tablet) administered orally every 24 hours (± 2) for the remaining doses. <br>At local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA, in place of remaining moxifloxacin doses, can receive linezolid 600 mg administered as a 1-hour IV infusion every 12 hours (± 2 hours) for the remaining doses.<br>Each site will document a blinding plan prior to study start. All blinded IV dosing will be maintained with a 12-hour schedule. IV bags will be blinded. <br>Subjects in the moxifloxacin arm, when on IV therapy, will receive once-daily active therapy via alternating doses of IV moxifloxacin and IV placebo every 12 (± 2) hours. <br>Subjects in the delafloxacin arm, when on oral therapy, will receive oral placebo moxifloxacin QD or IV placebo linezolid BID to maintain blinding. <br>Subjects in the moxifloxacin/linezolid arm, when on oral therapy or when meet criteria for oral therapy, will receive placebo delafloxacin oral formulation to maintain blinding.<br>",NA,Yes,NA
covid,RBR-876qb5,http://www.ensaiosclinicos.gov.br/rg/RBR-876qb5/,"This project will recruit 10 individuals of both sexes, with age between 18 and 80 years old, who have been diagnosed with COVID-19 infection confirmed by RT-PCR and with severe respiratory failure. All 10 patients will receive eculizumab intravenously once a week, at approximately the same time each day of application. The administered dose will be 900mg (each ampoule has 300mg in the concentration of 10mg / mL) every 7 days, in a 30 minute intravenous infusion without the need for an infusion pump, for 3 weeks (total of 3 doses of 900mg applied).<br>Laboratory tests will be performed weekly on all participants, before each dose of the drug (biochemical tests, blood count, inflammatory tests and complement dosage). For these tests, we will try to use the blood samples already collected to perform routine hospital tests, requested by the attending physician, in order to avoid additional venipuncture. Inflammatory tests will also be evaluated daily (according to the institutional protocol, in tests already collected in the care routine of Hospital das Clínicas). After finishing the treatment with the intervention, we will reassess the patients clinically weekly, during 4 weeks. This reassessment will be based on an interview, physical examination and laboratory tests.<br>There will be no control group in the study.;Drug;Complement Inactivator Proteins",NA,Yes,NA
im,RBR-96cy3k,http://www.ensaiosclinicos.gov.br/rg/RBR-96cy3k/,"After the randomization, 180 patients will be divided into 2 groups:<br><br>a) Intervention (90 patients): receive, intravenously, Magnesium Sulfate (60 mg/kg plus 0.9% saline solution in 100 ml final volume) for 15 minutes prior to anesthesia. After, this group will be divided into 3 groups of equal size (30 patients) according to the dose of Rocuronium to be used for anesthetic induction: 0.3mg/kg, 0.6mg/kg or 1.2mg/kg.<br><br>b) placebo (90 patients): 100ml receive saline 0.9% for 15 minutes prior to the anesthesia. Next, this group divided into 3 groups of equal size (30 patients) according to the dose of Rocuronium to be used for anesthetic induction: 0.3mg/kg, 0.6mg/kg or 1.2mg/kg.<br><br>;Drug;Anesthesia, General;Intubation, Intratracheal;Neuromuscular Blocking Agents",NA,Yes,NA
covid,RPCEC00000321,https://rpcec.sld.cu/en/trials/RPCEC00000321-En,"- Patients WITH invasive mechanical ventilation, CIGB-258 Peptide: 1 mg intravenously until extubation of the patient. Subsequently, the same dose and route is continued, every 24 hours, for three days. If there is no clinical, gasometric and radiological improvement after 72 hours, the dose may be increased to 2 mg, with a frequency of 12 hours (at the discretion of the physician). Never exceed 4 mg daily. - Patients WITHOUT invasive mechanical ventilation, CIGB-258 Peptide: 1 mg intravenously 1 mg every 24 hours until the patient reverses his condition (that is, that he does not require oxygen therapy and there are no signs and / or symptoms of acute respiratory failure). In case of unfavorable evolution and need for mechanical ventilation, the CIGB-258 therapeutic scheme is modified every 12 hours, detailed above (for patients with invasive mechanical ventilation).;Peptides;Peptide CIGB-258,        Jusvinza",NA,NA,NA
main,TCTR20190109001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4325,"A randomized, open-labeled, single-dose, two-way crossover design with two-period, two-treatment, two-sequence under fasting conditions and at least 7 days washout period between the doses., A randomized, open-labeled, single-dose, two-way crossover design with two-period, two-treatment, two-sequence under fasting conditions and at least 7 days washout period between the doses.",NA,NA,NA
im,TCTR20190614001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4533,"Group 1 : Tongue cleaning using mechanical and Chlorhexidine gluconate mouthwash. It has washout period 1 week and change into another mouthwash., Group 2 : Tongue cleaning using mechanical and Povidone iodine mouthwash. It has washout period 1 week and change into another mouthwash., Group 2 : Tongue cleaning using mechanical and tap water. It has washout period 1 week and change into another mouthwash.",NA,NA,NA
main,TCTR20190614007,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4900,"Sebium sensitive cream contains Bakuchiol, Ginkgo, and Mannitol (BGM complex), adapalene 0.1%/benzoyl peroxide 2.5% gel mono therapy",NA,NA,NA
im,TCTR20191025002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5306,"Take Trimethoprim/Sulfamethoxazole single strength (Trimethoprim 80 mg and Sulfamethoxazole 160 mg) 2 tabs oral thrice a week every Monday, Wednesday and Friday for pneumocystis jirovecii pneumonia prophylaxis until 1 month after chemotherapy cessation, Take placebo 2 tabs oral thrice a week every Monday, Wednesday and Friday for pneumocystis jirovecii pneumonia prophylaxis until 1 month after chemotherapy cessation",NA,NA,NA
